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Abstract
The human immunodeficiency virus (HIV) infection, that causes acquired immune
deficiency syndrome (AIDS), is a dynamic process that can be modeled via differential
equations. The primary goal of this thesis is to show how to drive any initial state
into an equilibrium, called the long-term nonprogressor, in which the infected patient
does not develop symptoms of AIDS. We first propose three control methods for HIV
treatment. These methods are designed for antiretroviral drug therapy and are based on
the understanding of the system dynamics. We apply these control strategies to several
HIV dynamic models as well as a general disease dynamic model. Then we derive a
new output feedback control scheme from one of the proposed methods. To show the
feasibility of the output feedback control, the HIV model is studied analytically. This
control method guarantees that the immune state is enhanced to a certain level, which
is enough for a typical patient to be driven into the long-term nonprogressor. We also
investigate methods to estimate approximately the state of the immune system based on
the available outputs of the HIV model. The feasibility and effectiveness of the control
strategies and estimation ideas are demonstrated by computer simulations.
Key Words. HIV dynamic model, AIDS, output feedback control, drug scheduling,
biological system analysis.
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Chapter 1
Introduction
The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome
(AIDS). The first cases of AIDS were reported in 1981, and two years later the HIV
was identified as the virus that causes AIDS [3]. After the initial HIV infection, the
virus resides in the blood of the HIV-positive patient, where it infects CD4 T-cells,
which are essential components1 of the human immune system [34]. An infected CD4
T-cell cannot fulfil its function in the immune system, and becomes a virus factory,
making multiple HIV copies. This process decreases the number of CD4 T-cells in the
HIV-infected patient. With a low level of CD4 T-cells, the immune system of a patient
cannot function properly, thus the patient is vulnerable to other infections [62]. In
modern clinical immunology a HIV patient is said to have AIDS when the patient has
less than 200 CD4 T-cells in each mm3 of blood [54]. In 2006, the estimated number of
people infected by HIV worldwide was 39.5 million and more than three-million people
died of AIDS [70].
1.1 Survey of the literature
The HIV infection process involves interactions among the virus, the immune system
and anti-retroviral drugs2. This process can be modeled mathematically (See [5, 11, 46,
1The cellular immune response in the human body employs T-cells to destroy body cells that have
been infected by the virus, and T-helper cells influence the activation of other T-cells. Therefore T-helper
cells are key components of the immune system.
2Since highly active anti-retroviral therapy (HAART) was developed in the late 1990s, it has succeeded
in reducing and maintaining virus load below detection level in many patients. However, about 25% of
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54, 55, 59] for specific models and [8] for general disease dynamic models). While the
study of the HIV infection is not a traditional control application, the control theory
literature provides some results concerning HIV treatment [22,29]. Model-based optimal
drug dosage problems in HIV treatment are studied in [32,47,48]. The drug-scheduling
method suggested in [72] relies on open-loop optimal control to maximize the inhibition
of HIV on the basis of measurements of the virus load. Finite-horizon open-loop control
is applied to a HIV chemotherapy model in [44], while continuous-time feedback control
schemes are used in [13, 33] for a dynamic model of HIV and lymphocytes, such as
CD4 T-cells and CD8 T-cells. In [30] open-loop optimal control tools are applied to a
simplified model obtained from [75].
Although HIV-infected patients are expected to develop AIDS, the possibility of a
long-term nonprogressor (LTNP) is reported with clinical data [9,50,56], and studied by
means of mathematical models3 describing the progress of the HIV infection [1,73,75,76].
LTNP is the status of a patient who has HIV, but also a sufficient number of CD4 T-cells
to fight off HIV and other infections. The mathematical model in [1, 73, 75, 76] with no
drug input has at least two asymptotically stable equilibria, one of which corresponds to
the AIDS status while the other corresponds to the LTNP status. Unfortunately, with
few exceptions, the parameters of the human body are such that the state of a HIV-
positive patient is located in the region of attraction of the equilibrium corresponding to
the AIDS status, rather than the LTNP status. Accordingly, patients without medication
normally progress to AIDS. It is obviously desirable that the state of the patient be driven
into the LTNP region of attraction, where the patient does not progress to AIDS and
drug treatment can be stopped.
This thesis focuses on the design of drug therapy to drive a patient to the LTNP
status. Structured treatment interruption (STI) which switches between zero and max-
imal medication has been suggested to solve this problem [73, 75, 76]. However, STI
scheduling depends on the values of the model parameters, and thus is vulnerable to
parametric uncertainty. In addition the results of [73, 75, 76] indicate the possibility of
attaining the LTNP status, but do not provide systematic drug-scheduling methods for
driving the patient to the LTNP status.
patients stop therapy within the first year on HAART because of side effects [38].
3A number of HIV models are available, but the LTNP phenomenon is described by only a few HIV
models in which the HIV specific immune modeling is sophisticated.
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In [82, 83] model predictive control (MPC) tools have been applied to the model
in [73] to determine when a full dose, or no medication, induce the LTNP status. This
problem has been studied with optimal control methods in [1,2,10]. Moreover, in [67–69],
optimal control theory has been applied to the disease dynamic model of [8]. A variation
of the scheme used in [82, 83], as well as the effect of using a continuous function of
drug efficiency, is considered in [65]. Although all these works show that the state of
a patient can be successfully driven into the LTNP region of attraction, these control
methods rely on the accurate and timely measurement of all of the model states, and
thus are unrealistic. In addition these works use various dynamic models with diverse
properties and rely heavily on the existence of optimal control laws, thus provide little
understanding of the immune response.
1.2 Contribution of the thesis
The primary goal of this thesis is to steer the state of the system describing a HIV
infected patient to the LTNP status. This is achieved by means of new methods of
treatment.
The first method is based on an approximation of higher order dynamics by a re-
duced order model. For the approximation we divide the HIV infection model into two
subsystems and modify one of the subsystems to emulate the whole system. With the
modification we relieve the difficulties associated with the high order model, such as
state observation and parameter estimation.
The second control method is known as gradual reduction of drug dose. By this
scheme it is possible to steer the state of any patient to the LTNP status if the model
parameters belong to certain parameter intervals. In order to justify the claim, we first
analyze the stability and the bifurcation properties of a HIV model and show that there
exists an equilibria curve towards the LTNP, which is locally stable for almost every
fixed constant input.
The third control method is derived from a new control philosophy which aims at
boosting the response of the immune system by means of drug scheduling. The control
strategy is implemented by controlled drug scheduling based on the understanding of the
immune boosting mechanism. The feasibility of the control methodology is illustrated
via simulations on a general disease model and on three HIV dynamic models, one of
13
which is a tristable HIV dynamic model.
This control perspective yields an output feedback method to control the immune
response. The suggested output feedback control idea guarantees that the immune state
is enhanced to a certain level, which is enough for a typical patient to be driven into the
long-term nonprogressor. To justify the control methodology the resulting controlled
HIV dynamic model is studied analytically.
Finally we investigate methods to estimate approximately the state of the immune
system on the basis of available outputs of the HIV model. We suggest two state esti-
mation methods, denoted as state inferences.
Experimental verification by clinical data is out of the scope of the thesis: we con-
centrate on model-based study as well as computer simulations to verify the feasibility
of the theoretical approach.
1.3 Organisation of the thesis
The thesis is organised as follows. In Chapter 2, Section 2.1 reviews some HIV models as
well as general models of disease dynamics. Section 2.2 surveys measurement methods for
the states of the HIV models, and discusses the relation between available measurements
and the states of the HIV models.
Chapter 3 is organised as follows. In Section 3.1 the problem considered in the
chapter is formulated, and in Section 3.2 the HIV model is modified to yield a reduced-
order model. Section 3.3 introduces a new control strategy for the modified model and
contains some simulation results. An improved control method with adapting reduced-
order model parameters is presented in Section 3.4. This chapter concludes with a
discussion of the results in Section 3.5.
Chapter 4 is organised as follows. In Section 4.1 and Section 4.2 we present the
bifurcation analysis of the HIV model in [40] to prepare for an application of gradual
reduction of drug dose. An example of gradual reduction of drug dose to the model is
discussed in Section 4.3. Section 4.4 summarises the result of the chapter.
Chapter 5 is organised as follows. In Section 5.1 we analyze the immune system,
develop a new strategy for drug dosage, and evaluate such a strategy by means of
simulations. The proposed strategy is then applied to the HIV model in [1] in Section 5.2,
and to the model of a general class of diseases in Section 5.3. In Section 5.4 we evaluate
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the control idea on an alternative HIV dynamic system, which possesses a tristability
property. Then Section 5.5 provides a summary and further remarks.
Chapter 6 is organised as follows. In Section 6.1 we describe the output feedback
control idea and its performances are demonstrated by means of computer simulations.
In Section 6.2 we analyze the controlled HIV model to show the control mechanism of
the output feedback strategy. Section 6.3 provides summary and conclusions.
Chapter 7 is organised as follows. Section 7.1 proposes a state apporximation method
based on continuous output injection , and the method is illustrated by means of com-
puter simulations. In Section 7.2 we suggest an alternative method to monitor the
immune status of the HIV infected patient taking into account implementation issues.
Section 7.3 describes further remarks.
We conclude this work in Chapter 8 with a summary of the main contributions of
the thesis in Section 8.1 as well as a discussion on future work in Section 8.2.
1.4 Published material
The works in Section 2.2 and Chapter 3 are included in [22] and [15]. The results in
Chapter 4 are presented in [17]. The results in Chapter 5 are published in [21], [16], [19],
and [18]. The works in Chapter 6 and Chapter 7 are included in [23] and [20] respectively.
In addition, the preliminary work for Chapter 4 is published in [27], and its applica-
tions are included in [25], [26], and [24]. The formal analysis and proofs for the work of
Chapter 4 are shown in [66] as well as [64].
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Chapter 2
Background material
This chapter provides an introduction to HIV models and to a general model of disease
dynamics, which are used throughout the thesis. In addition, some basic informations
on HIV measurements are given and discussed.
2.1 Introduction to HIV dynamic models
The interactions between HIV and immunocytes in the human body can be described
by means of several mathematical models. For a comprehensive explanation of HIV
infection modeling see [54] or [59].
Throughout the thesis the states of the models describe concentrations of specific
cells in a unit volume of blood and therefore are meaningful only when positive. The
model parameters which are used throughout the thesis are normalized so the state
variables do not represent actual data. For actual parameters in different HIV models
see [37, 59]. Moreover each patient practically has different system parameters. For
parameter estimation techniques in HIV models see [78].
2.1.1 HIV model with CTL-mediated immune response
In this section we recall the HIV infection model of [73], which allows to describe the
LTNP equilibrium. In particular the model describes the cytotoxic T lymphocyte (CTL)
response needed for the existence of the LTNP equilibrium. The model is described by
16
the equations
x˙ = λ− dx− ηβxy, (2.1)
y˙ = ηβxy − ay − p1z1y − p2z2y, (2.2)
z˙1 = c1z1y − b1z1, (2.3)
w˙ = c2xyw − c2qyw − b2w, (2.4)
z˙2 = c2qyw − hz2. (2.5)
As indicated in Table 2.1, x is the concentration of uninfected CD4 T-cells, y is the
concentration of infected CD4 T-cells, z1 is the concentration of helper-independent
CTLs, w is the concentration of CTL precursors, and z2 is the concentration of helper-
dependent CTLs.
State variable Clinical meaning
x Concentration of uninfected CD4 T-cell
y Concentration of infected CD4 T-cell
z1 Concentration of helper-independent CTL
w Concentration of CTL precursor
z2 Concentration of helper-dependent CTL
Table 2.1: Clinical meaning of the state variables of the HIV model (2.1)-(2.5).
The population of healthy (uninfected) CD4 T-cells increases at a rate λ (since the
cells are produced by the thymus), and decreases in the absence of HIV at a rate dx (since
the cells die naturally), which is proportional to the population of x. Uninfected CD4
T-cells are infected at a rate that is proportional to the product of x and y because the
CD4 T-cell x is a target of HIV and the infected CD4 T-cells y produce new virus. The
infected cell y dies out at a rate ay. In addition, the model describes the adaptive cell-
mediated immune system. This system consists of the precursor CTL w, which provides
long-term memory for a specific antigen, HIV in this case, as well as the effector CTL
z2, which has the role of destroying the infected cell y at the rate p2z2y. The cell w
differentiates into the cell z2 at the rate c2qyw. In other words, the model implies that
large populations of the infected cells y and of the precursor CTL w make the population
of z2 increase more rapidly. The term c2xyw in (2.4) implies that the precursor CTL
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w is generated at a rate proportional to the concentrations of x, y, and w. The helper-
independent component of the CTL response is represented in this model by z1. These
cells proliferate without CD4 T-cell help at the rate c1z1y, and destroy infected cells at
the rate p1z1y. For a detailed explanation of the model see [73,75].
The population of HIV is not explicitly shown in models (2.1)-(2.5) and the y state
corresponds to infected CD4 T-cell in this model. The state y can be regarded propor-
tional to the HIV load [12,31,73], because the turnover of HIV is much faster than that
of y [60]. That is to say, we accept the approximation v = Cpy, where v is the virus level
and Cp is a proportional parameter.
The quantity η, which varies between 0 and 1, describes the effect of the drug. In
the presence of a control input η can be written as
η = 1− ǫ∗u, (2.6)
where ǫ∗ is the maximal effect of the drug. For example, ǫ∗ = 0.98 indicates that the
maximal effect of the drug is 98%. From a control perspective, the input u, which has
values between 0 and 1, represents the drug dose of highly active anti-retroviral therapy
(HAART). If u = 1, a patient receives the maximal HAART therapy, while u = 0 means
no medication.
Note that, with the exception of Chapter 4 in the thesis, the drug input u is restricted
to be either 0 or 1 because the use of partially suppressive therapy (i.e., 0 < u < 1) is
difficult to achieve in practice [83]. In addition drug therapy at less than full dosage must
not be applied because of the high probability of emergence of drug-resistant strains of
HIV [83]. Consequently, equation (2.1) becomes x˙ = λ − dx − βxy when u = 0, or
x˙ = λ− dx− (1− ǫ∗)βxy when u = 1.
The remaining parameters λ, d, β, a, p1, p2, c1, c2, q, b1, b2, and h are positive con-
stants. The population of HIV is not explicitly modeled because it can be approximated
by y.
2.1.2 HIV model with immune response strongly dependant on target
cells
In this section we recall the model in [40]. The model is described by the equations
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x˙ = λ− dx−
n∑
i=1
βiyix, (2.7)
y˙i = (βix− ai − pizi)yi, i = 1, 2, 3, . . . , n, (2.8)
z˙i = (ciyix
2 − bi)zi, i = 1, 2, 3, . . . , n. (2.9)
The clinical meaning of each state is given in Table 2.2. For a detailed explanation of
the model (2.7)-(2.9) see [40].
Assume that only one viral strain exists (i.e., n = 1 in model (2.7)-(2.9)) and intro-
duce a control term η, yielding the model
x˙ = λ− dx− ηβyx, (2.10)
y˙ = (ηβx− a− pz)y, (2.11)
z˙ = (cyx2 − b)z. (2.12)
The quantity η describes the effect of the drug, and can be written as
η = 1− ǫ∗u, (2.13)
where ǫ∗ is the maximum effect of the drug. From a control perspective, the input u
represents the drug dose, which has values between 0 and 1. The remaining parameters
λ, d, β, a, p, c, and b are positive constants.
State variable Clinical meaning
x Concentration of uninfected CD4 T-cell
yi Concentration of infected CD4 T-cell by viral strain i
zi Concentration of immune reaction cell specific to viral strain i
Table 2.2: Clinical meaning of the state variables of the HIV model (2.7)-(2.9).
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2.1.3 HIV model with two target cell types
In this section we discuss the HIV model proposed in [1,2,10], which is described by the
equations
x˙1 =λ1 − d1x1 − (1− ǫ1u1)k1vx1, (2.14)
x˙2 =λ2 − d2x2 − (1− fǫ1u1)k2vx2, (2.15)
y˙1 =(1− ǫ1u1)k1vx1 − δy1 −m1zy1, (2.16)
y˙2 =(1− fǫ1u1)k2vx2 − δy2 −m2zy2, (2.17)
v˙ =(1− ǫ2u2)NT δ(y1 + y2)− cv −A1(x1, x2, u1)v, (2.18)
z˙ =λE +
bE(y1 + y2)
(y1 + y2) +Kb
z − dE(y1 + y2)
(y1 + y2) +Kd
z − δEz, (2.19)
where A1(x1, x2, u1) = (1− ǫ1u1)ρ1k1x1 + (1− fǫ1u1)ρ2k2x2.
As indicated in Table 2.3, x1 describes the uninfected CD4+ T-cell, x2 the uninfected
macrophage, y1 the infected CD4+ T-cell, y2 the infected macrophage, v the free virus,
and z the CTL effector.
State variable Clinical meaning
x1 Concentration of uninfected CD4+ T-cell
x2 Concentration of uninfected macrophage
y1 Concentration of infected CD4+ T-cell
y2 Concentration of infected macrophage
v Concentration of free virus
z Concentration of CTL effector
Table 2.3: Clinical meaning of the state variables of the HIV model (2.14)-(2.18).
The input terms u1 and u2 represent the antiviral effects from reverse transcrip-
tase inhibitors (RTI) and protease inhibitors (PI), respectively. For a comprehensive
explanation of the model see [1, 2, 10] and for further detail see [12,14].
2.1.4 HIV model with two immune response types
In this section we recall the model in [6]. The model describes the interaction between
infected and uninfected CD4 T-cells in the human body, including lytic and non-lytic
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components of the immune response to HIV infection. The model is described by the
equations
x˙ = λ− dxx− ηβyxN, (2.20)
x˙1 = λH +
αyx1
γ1 + y
− ǫx21 − ηβHyx1N, (2.21)
x˙2 = λH +
αyx2
γ2 + y
− ǫx22 − ηβHyx2N, (2.22)
y˙ = ηy[βx+ βHx1 + βHx2]N − dyy −Ky, (2.23)
where γ2 > γ1, K = K(x1, x2) = k1x1 + k2x2, and
N = N(x1, x2) =
1
1 + n1x1 + n2x2
.
As indicated in Table 2.4, x describes the concentration of uninfected CD4 T-cells which
do not play a role in the HIV-specific immune response, and y the concentration of
infected CD4 T-cells. x1 and x2 correspond to the concentrations of uninfected CD4
T-cells which participate in the HIV-specific immune response.
State Clinical meaning
x Concentration of uninfected CD4 T-cell
unrelated to the HIV-specific immune response
y Concentration of infected CD4 T-cell
x1 Concentration of uninfected CD4 T-cell
related to the HIV-specific immune response, type 1
x2 Concentration of uninfected CD4 T-cell
related to the HIV-specific immune response, type 2
Table 2.4: Clinical meaning of the state variables of the HIV model (2.20)-(2.23).
To deal with drug dosage as control input, we introduce the η term into the model.
The quantity η describes the effect of the drug. In view of the presence of a control
input, η can be written as
η(t) = 1− ǫ∗u(t),
where ǫ∗ is the maximum effect of the drug. From a control perspective the input
u represents the drug dose, which takes values between zero and one. Note that u is
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restricted to be either 0 or 1 as explained in Subsection 2.1.1. The remaining parameters
λ, λH , dx, dy, α, β, βH , γ1, γ2, ǫ, k1, k2, n1, and n2 are positive. For a detailed
explanation of the model see [6].
2.1.5 Disease dynamic model
In this section we describe a general disease dynamic model. In particular, we consider
the disease dynamic model given in [8, 67,69] and described by the equations
x˙1 = (a11 − a12x3)x1 + b1u1, (2.24)
x˙2 = a21(x4)a22x1(t− τ)x3(t− τ)− a23(x2 − x2∗) + b2u2, (2.25)
x˙3 = a31x2 − (a32 + a33x1)x3 + b3u3, (2.26)
x˙4 = a41x1 − a42x4 + b4u4, (2.27)
where the states x1, x2, x3 describe concentrations of specific cells in a unit volume of
blood and therefore are meaningful only when positive.
As indicated in Table 2.5, x1 describes the pathogenic antigen, x2 the plasma cells,
x3 the antibody, and x4 the relative characteristic of a damaged organ, where x4 = 0
indicates a healthy organ and x4 = 1 a dead organ.
State variable Clinical meaning
x1 Concentration of pathogenic antigen
x2 Concentration of plasma cells
x3 Concentration of antibody
x4 Concentration of relative characteristic of a damaged organ
Table 2.5: Clinical meaning of the state variables of the disease model (2.24)-(2.27).
This model is a modification of the mathematical model from [8], obtained by adding
therapeutic control inputs. Note that the model of [8] does not include any therapy
effects. The inputs are introduced for the model in [67, 69] and they are the pathogen
killer u1, the plasma cell enhancer u2, the antibody enhancer u3, and the organ healing
factor u4. Accordingly b1 < 0, b2 > 0, b3 > 0, and b4 < 0 [67,69]. τ and x2
∗ in (2.25) are
parameters which describe a pure time delay and a steady-state concentration of plasma
cells, respectively. For further detail on the model see [8,67,69].
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2.2 HIV measurements
HIV measurements are needed to monitor the status of a HIV-infected patient. In this
section we summarize the status of measurements related to HIV infection dynamics.
Several types of antibody tests, such as enzyme-linked immunosorbent assay (ELISA)
or western blot, are not discussed because these tests cannot give quantitative data on
the amount of the antibody. For additional information about HIV antibody testing
see [58].
2.2.1 Viral load tests
Viral load tests, which return the level of the y state in model (2.1)-(2.5), are also
known as viral load assays, polymerase chain reaction (PCR) tests, or branched de-
oxyribonucleic acid (bDNA) tests [3]. These tests work by looking for HIV genetic
material, the ribonucleic acid (RNA). Each test has a threshold viral level, below which
it cannot reliably detect HIV genetic material. This limit for clinical technology is cur-
rently 50 copies/ml [61], although some advanced experiments can detect HIV down to
5 copies/ml [52]. Each test is highly reliable and repeatable, and thus is used with a
CD4 T-cell count to monitor the progress of a HIV-infected patient.
2.2.2 Flow cytometry and CD4 T-cell count
Examination of lymphocyte populations is possible because their cell surface markers are
uniquely expressed. Monoclonal antibodies are used to identify T lymphocytes in human
blood [28]. These antibodies are labeled with fluorescent markers [62]. A flow cytometer
is designed to automate the analysis and separation of cells stained with fluorescent
antibodies. The flow cytometer uses a laser beam and a light detector to count single
intact cells in suspension (see Figure 2.1). Every time a cell with a fluorescent antibody
passes the laser beam, the cell is excited by the laser and emits light, which is deflected
and recorded by a detector. This instrument can sort populations of cells into various
containers according to their fluorescence.
In HIV treatment, the measurement of T-cell subpopulations, such as a subpopu-
lation of CD4 T-cells, is a key indicator of the prognosis of AIDS and it is routinely
performed by flow cytometric analysis. Although trained users of a flow cytometer can
obtain accurate results quickly and easily, this measurement method has limitations be-
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Figure 2.1: Basic flow cytometer [43]. A flow cytometer is designed to automate the
analysis and separation of cells stained with fluorescent antibody. The flow cytometer
uses a laser beam and light detectors to count single intact cells in suspension. Each
time a cell with a fluorescent antibody passes the laser beam, the cell is excited by the
laser and emits light, which is deflected and recorded by detectors.
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cause measuring specific cells requires the corresponding fluorescent antibody to stain
the target cells. For example, to measure unusual cells, the required antibody may be
costly or difficult to obtain [36].
2.2.3 Discussion on HIV measurements
Although a flow cytometer is a highly precise instrument, variability in the CD4 T-
cell count can be a significant problem [62]. For example, CD4 T-cell counts normally
undergo diurnal variation with fluctuation by as much as 150 to 300 copies/mm3, while
refrigeration of blood samples elevates the CD4 T-cell count. In addition, the CD4 T-
cell count increases as samples wait for processing. These variations make it difficult to
assess the real change in the CD4 T-cell population.
Meanwhile, since each viral load test has particular characteristics, results from dif-
ferent tests may not be comparable [3]. In particular, a pair of tests carried out on the
same sample of blood may vary significantly. Therefore, in clinical treatment the viral
load trend is more important than the individual viral load measurement.
Now consider the HIV model (2.1)-(2.5). In [22] we have assumed that the states x
and y are clinically measurable by means of polymerase chain reaction (PCR) test and
flow cytometry. PCR returns the level of HIV loads while a flow cytometer counts the
level of CD4 T-cells (see [39,53] for more information on PCR). The population of HIV
is not explicitly shown in the HIV model (2.1)-(2.5)1, and the y state corresponds to
infected CD4 T-cell in model (2.1)-(2.5). The state y is approximately considered as
proportional to the HIV load [12, 73], because the turnover of HIV is much faster than
that of y [60].
Although we have assumed that x corresponds to the CD4 T-cells measured by a
flow cytometer in [22], different assumptions are claimed in [1] because the result from
flow cytometer could include the number of infected CD4 T-cells as well as uninfected
CD4 T-cells. Nevertheless we can measure the number of infected CD4 T-cell y with the
help of PCR.
To this end, firstly we must separate white blood cells from blood sample of the HIV
patient by Ficoll-Hypaque method [49]. The PCR measures the number of HIV genome
[3], and an infected CD4 T-cell has the HIV genome in its cellular DNA. Consequently, if
1See Subsection 2.1.3 or [76] for HIV models including the population of HIV.
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PCR is performed with the separated white blood cells, then only the number of infected
CD4 T-cells y can be counted and the number of healthy CD4 T-cells x can be obtained
by subtracting y from the CD4 count (i.e., x+ y) of flow cytometry.
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Chapter 3
Control method based on a
reduced order model
This chapter describes a drug scheduling method based on a reduced-order model of the
HIV infection, which does not require estimates of all of the parameters and states of
the full-order model. We divide the full-order model into two subsystems, one of which
is modified to approximate the full-order model. We show that the suggested method
succeeds in driving the HIV patient state into the LTNP region of attraction. The works
in this chapter are included in [22] and [15].
3.1 Problem formulation
Consider the HIV model (2.1)-(2.5), introduced in Section 2.1.1, namely
x˙ = λ− dx− ηβxy, (3.1)
y˙ = ηβxy − ay − p1z1y − p2z2y, (3.2)
z˙1 = c1z1y − b1z1, (3.3)
w˙ = c2xyw − c2qyw − b2w, (3.4)
z˙2 = c2qyw − hz2. (3.5)
When a patient is treated it is desired that the drug be eventually terminated. To
investigate this possibility we determine the five equilibrium points of the model (3.1)-
(3.5) in Table 3.1. The stability properties of these equilibria are evaluated with the
parameter set of [73,82,83] given in Table 3.2. Under the assumption that η = 1, which
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corresponds to the case of no medication, the interpretation of each equilibrium is as
follows. Point A indicates the status of a person who does not have HIV. With the
parameters of Table 3.2 this equilibrium is unstable, which explains why it is difficult
to revert a patient, once infected, back to the HIV-free status when the medication is
stopped. Points C and E are locally exponentially stable. Point C is the status of a
patient for whom HIV dominates. Point E is for a HIV-positive patient who does not
progress to AIDS. For this reason this status is refered to as LTNP. With the parameters
of Table 3.2, the number y(E) of infected cells is low, while the number w(E) of CTL
precursors is large, which is desired. The control goal is to drive the state near this
equilibrium from any initial state. Note that the HIV patient state cannot be induced
to the LTNP status if full dose of HAART medication is applied everyday [25,27,65,73,
75,82,83]. Points B and D, which are unstable for the parameters of Table 3.2, are not
of interest for this discussion.
Point A x(A) = λ
d
, y(A) = 0, Unstable
(Healthy) z1
(A) = 0, w(A) = 0, z2
(A) = 0.
Point B x(B) = a
ηβ
, y(B) = ληβ−da
aηβ
, Unstable
z1
(B) = 0, w(B) = 0, z2
(B) = 0.
Point C x(C) = λc1
dc1+b1ηβ
, y(C) = b1
c1
, LES
(AIDS) z1
(C) = ηβx
(C)
−a
p1
, w(C) = 0, z2
(C) = 0.
Point D x(D) = λ
d+ηβy(D)
, y(D) =
[c2(λ−dq)−b2ηβ]+
√
[c2(λ−dq)−b2ηβ]2−4ηβc2qdb2
2ηβc2q
, Unstable
z1
(D) = 0, w(D) = hz2
(D)
c2qy(D)
, z2
(D) = y
(D)(c2ηβq−c2a)+b2ηβ
c2p2y(D)
.
Point E x(E) = λ
d+ηβy(E)
, y(E) =
[c2(λ−dq)−b2ηβ]−
√
[c2(λ−dq)−b2ηβ]2−4ηβc2qdb2
2ηβc2q
, LES
(LTNP) z1
(E) = 0, w(E) = hz2
(E)
c2qy(E)
, z2
(E) = y
(E)(c2ηβq−c2a)+b2ηβ
c2p2y(E)
.
Table 3.1: Equilibrium points of the model (3.1)-(3.5) [25]. All stability properties are
based on the typical parameter set of Table 3.2.
To analyze the model (3.1)-(3.5), let X := [x, y, z1, w, z2]
T and let U be the set of
measurable functions on [0,∞) with values between 0 and 1. Note that the input η(·)
of interest is in U . Also, let P = [0,∞)5.
Theorem 1 Consider the system (3.1)-(3.5). For every input function η(·) ∈ U , finite-
time escape cannot occur, and the set P is positively invariant. In other words, for every
η(·) ∈ U and initial condition X(0) ∈ P, the solution X(t) of (3.1)-(3.5) exists for all
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λ d β a p1 p2 c1 c2 q
1 0.1 1 0.2 1 1 0.03 0.06 0.5
b1 b2 h ǫ
∗ x(0) y(0) z1(0) w(0) z2(0)
0.1 0.01 0.1 0.9799 0.2913 3.3333 0.0913 0.0100 0.0100
Table 3.2: Parameters and initial conditions for model (3.1)-(3.5). All simulations in
this chapter use these typical parameters, which are taken from [73,82,83].
t ≥ 0, and is contained in P for all t ≥ 0.
Proof: Let X(0) ∈ P and assume that some component of X(t) escapes at the finite
time T > 0. Since (3.2), (3.3), and (3.4) have the linear form y˙(t) = fy(t)y(t), z˙1(t) =
fz1(t)z1(t), and w˙(t) = fw(t)w(t), where fy(t), fz1(t), and fw(t) are continuous on [0, T ),
the states y(t), z1(t), and w(t) remain positive for 0 ≤ t < T . During this time interval
the states x(t) and z2(t) also remain positive since y(t) and w(t) are continuous and
positive, x˙ > 0, and z˙2 ≥ 0 by (3.1) and (3.5) for x = 0 and z2 = 0, respectively. Hence
X(t) ∈ P for 0 ≤ t < T . Now define V (t) := x(t) + y(t), which is positive for all
t ∈ [0, T ). Then
V˙ = λ− dx− ay − p1z1y − p2z2y
≤ λ− k(x+ y)
= λ− kV,
where k = min{d, a}. Thus V (t) (and hence, x(t) and y(t)) is bounded on the interval
0 ≤ t < T . Indeed, for 0 ≤ t < T , the functions fz1(t) = c1y(t) − b1 and fw(t) =
c2x(t)y(t)−c2qy(t)−b2 are bounded. Therefore, z1(t) and w(t) do not diverge to infinity
by boundedness of fz1(t) and fw(t). Then, by (3.5), z2(t) is also bounded. Hence finite
escape does not occur and P is positively invariant 
3.2 Modification of the model
3.2.1 Separation of the model
We consider the full-order model (3.1)-(3.5) as the interconnection of two subsystems:
the infection dynamics and the immune system. The infection dynamics are modeled by
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Figure 3.1: Interconnection between the infection dynamics and the immune system.
means of the two-dimensional nonlinear system
x˙ = λ− dx− β(1− ǫ∗u)xy, (3.6)
y˙ = β(1− ǫ∗u)xy − ay − (p1z1 + p2z2)y, (3.7)
with inputs u and p1z1 + p2z2, and outputs x and y.
The immune system is modeled by the three-dimensional nonlinear system
z˙1 = c1z1y − b1z1, (3.8)
w˙ = c2xyw − c2qyw − b2w, (3.9)
z˙2 = c2qyw − hz2, (3.10)
with inputs x and y, and output p1z1 + p2z2. The interconnection of these subsystems
is shown in Figure 3.1.
We consider the full-order model (3.1)-(3.5) as the interconnection of two nonlinear
systems for several reasons. Firstly, it is currently not possible to measure all the states
of the full-order model (3.1)-(3.5) with high accuracy [83]. In particular, as discussed in
Section 2.2, we can assume that the CD4 T-cells x and the HIV loads y are measured
accurately. Therefore the system (3.6), (3.7) includes the states that can be measured
reliably, whereas the system (3.8)-(3.10) has unmeasured states.
Secondly, it might be impossible to estimate the parameters of the immune system
due to the lack of measurements of the immune system states. Even if estimation were
possible, it may be impractical to estimate these parameters for each HIV patient. For
additional information about parameter estimation in HIV dynamic models, see [77,78].
Thirdly, although the full-order model (3.1)-(3.5) describes the human immune sys-
tem with both helper-dependent CTL and helper-independent CTL, the immune system
is only approximately modeled by a low-order system of differential equations. Therefore
we separate the well-modeled part (3.6), (3.7) from the poorly1 modeled part (3.8)-(3.10).
1The model in [12] has an alternative immune system, which is different from (3.8)-(3.10).
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In the infection dynamics (3.6), (3.7), we can regard the effect on the virus load from
the immune system (3.8)-(3.10) as the positive function φ(z1, z2) = p1z1 + p2z2 acting
on (3.7). The system (3.6), (3.7) consists of the model used in [54] as well as the func-
tion φ, which corresponds to the control effect of the virus load produced by the system
(3.8)-(3.10). By appending φ, the virus dynamic model of [54] becomes the system (3.6),
(3.7).
For these reasons we seek a control method that depends only on (3.6), (3.7). To
realize such a method, we note that (3.7) includes the states z1 and z2, while (3.6) has
only the states x and y. Our goal is thus to modify (3.7) so that the modified system
exhibits dynamic behaviour similar to that of the full-order model (3.1)-(3.5) over short
time intervals.
3.2.2 Construction of the reduced-order model
The full-order model (3.1)-(3.5) has two asymptotically stable equilibria with the typical
parameter set. Therefore, when u = 0, the modified infection dynamics must have anal-
ogous equilibria for these parameters. Thus, as a candidate2 for the modified infection
dynamics we consider the reduced-order model
x˙ = λ− dx− β(1− ǫ∗u)xy, (3.11)
y˙ = −βǫ∗uxy +A+By + Cy2 +Dy3, (3.12)
where A, B, C, and D are real numbers with D nonzero. When u = 0, (3.11), (3.12)
becomes
x˙ = λ− dx− βxy, (3.13)
y˙ = A+By + Cy2 +Dy3. (3.14)
The equilibria of (3.14) are determined by solving
A+By + Cy2 +Dy3 = 0. (3.15)
The full-order model (3.1)-(3.5) has two asymptotically stable equilibrium points when
u = 0. In order for the reduced order model (3.11), (3.12) to have two stable equilibria
2This is a possible candidate which has been found through a number of trials. Another candidate
can exist for the approach of this chapter.
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with u = 0, (3.15) must have three real solutions, namely, K1, K2, and K3, where
K1 < K2 < K3. Then A, B, and C are such that
A = −DK1K2K3,
B = D(K1K2 +K2K3 +K3K1),
C = −D(K1 +K2 +K3).
If D > 0 then K2 is an asymptotically stable equilibrium of (3.14) whereas K1 and K3
are unstable. If D < 0 then K1 and K3 are asymptotically stable equilibria of (3.14)
whereas K2 is unstable (see Figure 3.2). Therefore D must be negative. In addition
K1 > 0 guarantees the existence of two asymptotically stable equilibria with positive y.
Consequently the values λ
d+βK1
and λ
d+βK3
of x for the two equilibria are also positive
since K1, K3, and parameters are positive. Note that D < 0 implies existence and
boundedness of all trajectories of the model (3.13), (3.14).
Figure 3.2: Graphs of y and y˙ in equation (3.14). The left and the right graphs
correspond to the cases with D < 0 and D > 0, respectively. It is assumed that
0 < K1 < K2 < K3. The dark dot in the graphs implies asymptotic stability of the
equilibrium point whereas the white dot indicates instability of the point.
If the initial value of y is between 0 and K2, then y(t) tends to K1. Then x(t) tends
to λ
d+βK1
according to (3.13). If an initial state has a value of y greater than K2, then
y(t) tends to K3, and x(t) tends to
λ
d+βK3
. Therefore, the two-dimensional region of
attraction for the equilibrium ( λ
d+βK1
,K1) is 0 < y < K2 while the two-dimensional
region of attraction for the equilibrium ( λ
d+βK3
,K3) is y > K2.
With the typical parameter set and u = 0, the full-order model (3.1)-(3.5) has five
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equilibria, namely, (10, 0, 0, 0, 0), (0.2, 4.9, 0, 0, 0), (0.2913, 3.3333, 0.0913, 0, 0),
(0.6079, 1.5451, 0, 0.8799, 0.4079), and (8.2255, 0.0216, 0, 1240, 8.0255). Only the
third and the fifth equilibria are asymptotically stable. Thus the y component 3.3333
of the third equilibrium is chosen as K3 while the y component 0.0216 of the fifth is
chosen as K1. Consequently, for u = 0, the reduced-order model (3.11), (3.12) has two
asymptotically stable equilibria, namely, (0.2913, 3.3333) and (8.2255, 0.0216). Note that
the modified reduced-order model will emulate the full-order system in a short period
to present the effect of the immune system in those equilibria.
D and K2 remain undetermined. At this point, we know only that K1 < K2 < K3,
D < 0, and |D| must be sufficiently small. If |D| is large and u = 1, then, with the
typical parameters, the dynamics of (3.11), (3.12) do not vary dramatically whereas
those of the full-order model (3.1)-(3.5) do. In the next section it is assumed that D and
K2 are fixed and a control methodology is presented.
3.3 Control strategy with constant parameters
In this section we assume that D and K2 are constant and design a control strategy
denoted as CSCP. With the above assumption all the parameters of (3.11), (3.12) are
determined. The basic concept of the control strategy is that the low-order system
(3.11), (3.12) for the modified infection dynamics is used as an emulator of a high-order
system, the HIV patient.
The idea of using the reduced-order model (3.11), (3.12) in HIV treatment is as
follows. We assume that the patient has HIV measurement tests at the beginning of a
period of length T . Within the period T the reduced-order model (3.11), (3.12) exhibits
dynamic behaviour similar to that of the high-order system. From HIV measurements
(see Section 2.2), the CD4 T-cell count and viral load can be thought of as the values
of the states x and y, respectively. Therefore we set these levels as the initial values
for (3.11), (3.12) at the beginning of the period. During the period we consider (3.11),
(3.12) as an emulator of the patient. Then we estimate the CD4 T-cell count and viral
load of the patient by referring to the states x and y of (3.11), (3.12), respectively. The
HIV measurements of the patient are available only once in each period, whereas the
states x and y of the reduced-order model (3.11), (3.12) are available as desired by means
of numerical integration. See Figure 3.3 for the configuration of the controlled system.
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Figure 3.3: Diagram describing the configuration of the controlled system with reduced-
order model. Note that (x, y) of full-order model is considered as discrete time input to
reduced-order model.
Using (3.11), (3.12) we decide whether the anti-HIV therapy is taken each day. In
other words the states x and y of the reduced-order model (3.11), (3.12) are available
at the beginning of each day by means of numerical integration. This decision depends
only on the value of y because y = K2 is the boundary of the LTNP region of attraction
in the reduced-order model (3.11), (3.12). If the state y of the reduced-order model
(3.11), (3.12) is lower than K2 at the beginning of the day, the anti-HIV medication is
not administered to the patient for the day. Otherwise the medication is administered
to the patient.
3.3.1 Control steps of CSCP
The idea of CSCP is realized by the following steps. Note that time is measured in days.
Initialization. Three positive numbers T , N , and K2, a negative number D, and
a function uD(t) (0 ≤ t ≤ 1 day) of daily drug effect are chosen. T denotes the time
period between each set of HIV measurements, while N denotes the total number of HIV
measurements during medication. Therefore the period of total medication is NT days.
Let nT denote the number of days after the last HIV measurement and let nN denote
the number of HIV measurements after the beginning of the medication. Therefore, with
the initialization nT = 0 and nN = 0, a generic day of the treatment can be denoted as
the (nNT + nT )th day.
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Figure 3.4: Control strategy with constant parameters (CSCP) D and K2.
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STEP 1. The present CD4 T-cell count and viral load are measured and xM (nNT )
and yM (nNT ) are set from these measurements. The subscript M indicates that the
values are obtained from measurements. Set xI(nNT ) = xM (nNT ) and yI(nNT ) =
yM(nNT ). The subscript I indicates the initial value for the reduced-order model (3.11),
(3.12) for each day.
STEP 2. At the beginning of each day, if yI(nNT+nT ) ≥ K2, then full drug therapy
is applied to the HIV patient and the input u(nNT + nT + t) = uD(t) (0 ≤ t ≤ 1 day)
applied to the reduced-order model (3.11), (3.12). Otherwise no medication is applied
and the input u(nNT + nT + t) = 0 (0 ≤ t ≤ 1 day) is applied to the reduced-order
model (3.11), (3.12).
STEP 3. Integrate the reduced-order model (3.11), (3.12) for one day with the
initial point (xI(nNT + nT ), yI(nNT + nT )) and the input u(nNT + nT + t). Set xF =
x(nNT + nT + 1) and yF = y(nNT + nT + 1), where the subscript F indicates the final
value of the state of the reduced-order model (3.11), (3.12).
STEP 4. If nT = T then go to STEP 5. Otherwise increase nT by one, set
xI(nNT + nT ) = xF , yI(nNT + nT ) = yF , and go to STEP 2.
STEP 5. If nN = N then terminate this routine. Otherwise set nT = 0, increase
nN by one, and go to STEP 1.
A flow chart illustrating these control steps is given in Figure 3.4.
3.3.2 Simulations of CSCP
In this subsection two computer simulations of the CSCP are presented. We regard
the full-order model (3.1)-(3.5) as the HIV patient in the simulations. All simulations
use the typical parameters of [73, 82, 83] and one of the initial conditions of [82, 83], as
indicated in Table 3.2. Note that the initial point is in the vicinity of Point C when
u = 0, which corresponds to a seriously progressed HIV infection. The design variables
are defined as K1 = 0.0216, K2 = 1.5451, K3 = 3.3333, D = −0.6, N = 600, T = 4 for
the first simulation, and T = 7 for the second simulation. K1 and K3 are determined as
discussed in the previous section.
The value K2 = 1.5451 is selected according to Table 3.1 as the only equilibrium
value of y such that K1 < K2 < K3. We assume that the daily drug treatment implies a
square-wave profile of u during the day because HAART drugs are usually taken orally
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at fixed doses and the drug absorption dynamics cannot be manipulated arbitrarily. In
particular the function of the one-day drug effect uD(t) (0 ≤ t ≤ 1 day) is assumed to
be given by
uD(t) =

 1, if 0 ≤ t ≤ 0.6 day,0, if 0.6 < t ≤ 1 day.
Figure 3.5: Simulation result of the control strategy with constant parameters D and
K2, and with T = 4. The unit of x and y is (100copies/µl).
In the first simulation of this strategy (Figure 3.5), the drug therapy is terminated
around the 200th day by the suggested control routine. After the termination of the
therapy, x(t) and w(t) increase slowly, and y(t) decreases slowly in the full-order model
(3.1)-(3.5). The state in the full-order model (3.1)-(3.5) is successfully driven to the
LTNP status3 because T is sufficiently small that the reduced-order model (3.11), (3.12)
emulates the behaviour of the full-order model (3.1)-(3.5), although the reduced-order
model (3.11), (3.12) uses constant values of D and K2.
3For recent data of treatment interuption in HIV therapy, see [7] where ‘STACCATO’ trials have
been reported with physical experiments. The treatment decision making method used in ‘STACCATO’
trials is based on the level of CD4 T cell. A comparison study of the theoretical approach of this thesis
and the clinical data provided by experimental works such as [7] should be carried out in the future.
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Figure 3.6: Simulation result of the control strategy with constant parameters D and
K2, and with T = 7. The unit of x and y is (100copies/µl).
However, in the second simulation of the strategy (Figure 3.6), the drug treatment
does not end within the length of the simulation. The strategy fails to bring the HIV
patient to the LTNP status because T is too large for (3.11), (3.12) to emulate (3.1)-(3.5)
effectively with fixed D and K2.
3.4 Control strategy with time-varying parameters
Figure 3.6 shows a recurring pattern in the simulation. This pattern implies that CSCP
fails to drive the state into the LTNP region of attraction. To break this pattern we
modify the values of D and K2 during the medication and design a control strategy with
varying parameters (CSVP). If we adjust D and K2 once every period T , the occurrence
of this pattern can be prevented. In this section a method for adjusting D and K2 is
described and illustrated.
At the beginning of a new period, let t = nNT . From the previous period we know
the initial point (xM (nNT−T ), yM (nNT−T )) of the reduced-order model (3.11), (3.12),
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the final point (xF , yF ) of the reduced-order model (3.11), (3.12), the values of D and
K2, and the history of the input u(t), where nNT − T ≤ t ≤ nNT . In addition we
can find the current levels of the CD4 T-cell count and viral load (xM (nNT ), yM (nNT ))
from measurements on the HIV patient. Although particular values of D and K2 are
used for the previous period, there may exist alternative values of D and K2 that reduce
the error between the reduced-order model (3.11), (3.12) and the patient, i.e., model
(3.1)-(3.5). We define the difference ε = yF − yM (nNT ) between yF and yM (nNT ) as
the error between the reduced-order model (3.11), (3.12) and the patient. Figure 3.7
shows a conceptual representation of the initial point of the reduced-order model (3.11),
(3.12) for the previous period, the final point of the reduced-order model (3.11), (3.12),
the current HIV measurements (CD4 T-cell count and viral load) of the HIV patient,
and the error.
Figure 3.7: A conceptual figure depicting the state trajectories of the real system and
of the reduced-order model (3.11), (3.12).
To find such values of D and K2 we consider a rectangular region in the vicinity
of the previous values of D and K2, and solve an optimization problem to minimize ε
2
within the rectangular region.
3.4.1 Control steps of CSVP
To realize the CSVP we use the steps of the CSCP with modifications to Initialization
and STEP 5, called Initialization′ and STEP 5′, respectively. Initialization′ for the CSVP
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consists of Initialization used in the CSCP together with the selection of the positive
numbers δD and δK2. STEP 5
′ for CSVP is as follows.
STEP 5′. If nN = N , terminate this routine. Otherwise set nT = 0 and increase
nN by one. The present CD4 T-cell count and viral load are measured and xM (nNT )
and yM(nNT ) are set from these measurements. Let D
∗ and K2
∗ be the current values
of D and K2, respectively. Find new D and K2 satisfying
min
D ∈ [D∗ − δD, D∗ + δD]
K2 ∈ [K2
∗
− δK2, K2
∗ + δK2]
(y∗(nNT )− yM (nNT ))2 , (3.16)
where y∗(nNT ) is the y component of the solution of the reduced-order model (3.11),
(3.12) for the initial point (xM (nNT−T ), yM (nNT−T )) and the input function u(nNT−
T + t), where 0 ≤ t ≤ T . Set xI(nNT ) = xM (nNT ), yI(nNT ) = yM (nNT ), and go to
STEP 2.
A flow chart for the CSVP is shown in Figure 3.8.
3.4.2 Simulation of CSVP
All system parameters, the initial point, and the design variables except D and K2 are as
in the simulation in which the HIV patient does not reach the LTNP status if the CSCP
is used. The initial values of D and K2 are set as −0.6 and 1.5451, respectively. Also,
both δD and δK2 are defined as 0.1. To solve the minimization problem numerically we
use the Optimization Toolbox of MATLAB.
For the first 7 days all the trajectories in Figure 3.9 are the same as those of the
simulation shown in Figure 3.6. Thereafter, once every period, the control method
adjusts the parameters D and K2 used by the reduced-order model (3.11), (3.12) to
emulate the behaviour of the full-order model (3.1)-(3.5). Although T is the same as in
the simulation shown in Figure 3.6, the patient state is induced to the LTNP status in
this case. Moreover the state in Figure 3.9 converges faster than the state in Figure 3.5.
In the meantime, as shown in Figure 3.9, the behaviour of the reduced-order model
(3.11), (3.12) approaches that of the full-order model (3.1)-(3.5) at each period with a
steady series of square-wave inputs u(t). On the contrary, from the 100th day to the
350th day, where the input u(t) switches twice in each period T , the full- and reduced-
order models do not show similar behaviour.
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Figure 3.8: Control strategy with time-varying parameters (CSVP) D and K2.
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Figure 3.9: Simulation result of the control strategy with varying parameters D and K2
when T = 7. The unit of x and y is (100copies/µl).
3.5 Conclusions
In this chapter we have shown how the suggested control strategies can drive the HIV
patient’s state to the LTNP status. The works in this chapter are presented in [22]
and [15]. All the results in the chapter are based on the HIV dynamics model (3.1)-
(3.5). Thus more research is needed for other HIV models. In the next chapter we will
discuss on a HIV model and analyse a bifurcation property in order for a continuous
drug variation to be applied.
We now comment on the assumptions that are made in the simulations, and also
discuss an idea for improving the given results.
1. It is assumed that the full-order model (3.1)-(3.5) accurately describes the dy-
namics of the HIV patient. Hence the two-dimensional system (3.11), (3.12) can
emulate the five-dimensional system (3.1)-(3.5). However this fact does not mean
that the control method is guaranteed to work clinically. It is necessary to consider
more detailed models of the real system and to work with clinicians. For example
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the model in [47] is a ten-dimensional model including a continuously mutating
viral population but does not contain dynamics relating to the human immune
system.
2. Although viral load test results are obtained in practice within ten days to two
weeks [3], this measurement delay is not considered in the simulations in this
chapter. Hence some modifications of the simulations and a more involved control
scheme are required.
3. We assume that uD(t) is a square wave of amplitude 1 with 1-day time period and
60% width. However the dynamics of drug effect in the human body cannot be
assumed to be a square wave. Further modeling of the drug delivery dynamics
must be included in the full-order model (3.1)-(3.5).
4. In this chapter, the behaviour of the reduced-order model (3.11), (3.12) approaches
that of the full-order model (5.1)-(5.5) at each period with a steady series of square-
wave inputs u(t), as shown in Figure 3.9. On the contrary, from the 100th day to
the 350th day, where the input u(t) switches twice in each period T , the full- and
reduced-order models do not show similar behaviour. To increase the similarity
between the behaviour of the full-order model (5.1)-(5.5) and that of the reduced-
order model (3.11), (3.12), we can use the reduced-order model (3.11), (3.12) when
u(t) = 0 and an alternative model when u(t) = 1. Currently, the reduced-order
model (3.11), (3.12) is used for both u(t) = 0 and u(t) = 1, but this model is
designed to emulate the full-order model (5.1)-(5.5) only when u(t) = 0.
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Chapter 4
Control method by gradual
reduction of drug dose
Recently a control strategy based on gradual reduction of drug dose (GRDD) has been
proposed to induce CTL mediated control and to achieve the LTNP status [27, 66]. In
this chapter we apply this drug scheduling scheme to a HIV model with immune system
which strongly depends on the HIV target cells. By means of this method the HIV
patient is steered to the LTNP status. The results in this chapter are presented in [17].
In addition, the preliminary work for this chapter is published in [27], and its appli-
cations are included in [25], [26], and [24]. The formal analysis and proofs for the work
of the chapter are shown in [66] as well as [64].
4.1 Gradual reduction of drug dose and HIV model with
immune response strongly dependant on target cells
GRDD, also known as gradual dose reduction (GDR), is a drug prescription scheme
to taper off the drug medication level. This drug scheduling scheme is now considered
in some clinical cases, such as long-term uses of neuroleptic, antidepressant or benzo-
diazepine for chronic patients [51, 71, 80]. In [27] GRDD has been introduced for HIV
treatment to induce the patient state to the LTNP, see also [24–26]. A mathematical
analysis of GRDD for the model in [75] has been performed in [66].
The scheme of GRDD is based on the bifurcation properties of the HIV model. In
this chapter we consider the model (2.10)-(2.12), discussed in Section 2.1.2. We recall
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Point F x(F ) = λ
d
, y(F ) = 0, z(F ) = 0.
Point G x(G) = a
ηβ
, y(G) = ληβ−ad
aηβ
, z(G) = 0.
Point H x(H) =
λc+
√
λ2c2−4bcdηβ
2cd , y
(H) = b
c(x(H))2
, z(H) = ηβx
(H)
−a
p
.
Point I x(I) =
λc−
√
λ2c2−4bcdηβ
2cd , y
(I) = b
c(x(I))2
, z(I) = ηβx
(I)
−a
p
.
Table 4.1: Equilibrium points of the model (4.1)-(4.3).
the model here for convenience:
x˙ = λ− dx− ηβyx, (4.1)
y˙ = (ηβx− a− pz)y, (4.2)
z˙ = (cyx2 − b)z. (4.3)
The model has four equilibrium points: Point F, Point G, Point H, and Point I (see Table
4.1). Without any medication (i.e., η = 1), Point G and Point H are asymptotically
stable [40].
We stress that Point G corresponds to the status of a patient for whom HIV domi-
nates, whereas Point H corresponds to the status of a patient who does not progress to
AIDS, i.e., the LTNP status.
4.2 Preliminary analysis of gradual reduction of drug dose
Let X := [x, y, z]T and let U be the set of measurable functions whose values are between
0 and 1. Therefore, the input η(·) of interest is in U . Also, let P = R3+ = [0,∞)3.
Theorem 2 Consider the system (4.1)-(4.3). For any η(·) ∈ U , no finite escape time
phenomenon occurs and the set P is positively invariant. In other words, for any initial
condition X(0) ∈ P, the solution X(t) of model (4.1)-(4.3) exists for all t ≥ 0 and is
contained in P for all t ≥ 0.
Proof: Suppose that X(0) ∈ P and that some components of X(t) shows finite escape
time phenomenon at a finite time T > 0. Since (4.2) and (4.3) have the linear form
y˙(t) = fy(t)y(t) and z˙(t) = fz(t)z(t), where fy and fz may be regarded as continuous
functions of time whose values exist for 0 ≤ t < T , the states y(t) and z(t) remain
positive for 0 ≤ t < T . (Note that y˙ and z˙ go to zero when y and z approach to zero,
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respectively, and also y˙ = 0 and z˙ = 0 when y = 0 and z = 0, respectively.) Since (4.1)
has the form x˙(t) = λ+ fx(t)x(t), where fx may be regarded as a continuous function of
t for 0 ≤ t < T , it can be seen by means of a comparison lemma [42] that the state x(t)
also remains positive in this time interval. This implies that X(t) ∈ P for 0 ≤ t < T ,
regardless of η(·). Now let V (t) := x(t) + y(t), which is positive for all t ∈ [0, T ). Then,
let k = min{d, a} and note that
V˙ = λ− dx− ay − pzy ≤ λ− k(x+ y) = λ− kV.
Thus V (t) (as well as x(t) and y(t)) is bounded in the interval 0 ≤ t < T . This in
turn implies that finite escape does not occur. Indeed, for 0 ≤ t < T , the function
fz(t) = (cy(t)x(t)
2− b) is bounded, and therefore, z(t) is bounded. So we conclude that
T equals infinity. 
Assumption 1 The parameters of model (4.1)-(4.3) are such that
d < a, (4.4)
2ad < λβ, (4.5)
4dβ
λ2
<
c
b
, (4.6)
β3
a(λβ − ad) >
c
b
. (4.7)
Although Assumption 1 is technically designed to subsequent analysis of this chapter
and the model parameters are normalized so the state variables do not represent actual
data, Assumption 1 can be justified by previous works in the literature on HIV dynamics
such as [54,75], as seen in what follows.
Inequality (4.4) implies that the decay rate of the uninfected cells is smaller than
that of the infected cells [54]. Inequality (4.5) implies the basic reproductive ratio [54] is
larger than 2. For small basic reproductive ratio, the virus is automatically eradicated
and the patient needs not be treated. However this is apparently not the case for most
AIDS patients.
Regarding inequality (4.6), it is noted that if the immune responsiveness c lies below
a threshold, treatment cannot result in the establishment of CTL memory [75]. While
any formula for such a threshold is not presented in the literature, the condition (4.6)
might be understood as a possible lower bound for the immune responsiveness.
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Inequality (4.7) limits the size of β. In [75], it is mentioned that ‘If the rate of viral
replication β is below a threshold..., an effective CTL response is always established.’
This means that, for too small β, LTNP is automatically achieved so that the patients
need not be treated at all (note that this is not the case for most AIDS patients in the
real world), hence β should be lower-bounded. The HIV literrature has not presented
any quantitative criterion regarding this, but the conditions (4.7) could be understood
for such bound.
Lemma 1 Suppose Assumption 1 holds.
1. The quantity inside the square-root term of Point H and Point I (see Table 4.1) is
positive for all values of 0 < η ≤ 1 (therefore the system has four real equilibrium
points for all η).
2. Point F and Point G coincide when
η = η¯FG =
ad
λβ
.
Moreover 0 < η¯FG <
1
2 .
3. Point G and Point H coincide when η = η¯GH , where the solutions of
Y (η) = bβ3η3 − acλβη + a2cd = 0 (4.8)
are η∗1, η¯GH and η
∗
3 (η
∗
1 < η¯GH < η
∗
3). Moreover η¯FG < η¯GH < 1.
4. z(H) > 0 when η¯GH < η ≤ 1.
Proof:
1. The term under the square-root of Point H and Point I is λ2c2 − 4bcdηβ. When
η = 1 this term achieves its minimum, namely λ2c2 − 4bcdβ, which is positive by
(4.6). Therefore all four points are real for any η.
2. By solving the equations x(F ) = x(G) and y(F ) = y(G) we obtain that Point G =
(λ
d
, 0, 0) if and only if η = ad
λβ
. Also ad
λβ
is positive and less than 12 by (4.5).
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3. y(G) = y(H) and z(G) = z(H) imply Y (η) = 0. By (4.5) and (4.7)
Y (−∞) < 0,
Y (0) = a2cd > 0,
Y (η¯FG) = bβ
3 a
3d3
λ3β3
− acλβ ad
λβ
+ a2cd = b
a3d3
λ3
> 0,
Y (2η¯FG) = bβ
3
(
2ad
λβ
)3
− acλβ 2ad
λβ
+ a2cd < a2bd
(
4d(λβ)
λ3
− c
b
)
< 0,
Y (1) = bβ3 − acλβ + a2cd = ba(λβ − ad)
(
β3
a(λβ − ad) −
c
b
)
> 0.
Thus the third-order algebraic equation Y (η) = 0 has three real solutions η∗1 , η¯GH ,
and η∗3 such that η
∗
1 < η¯GH < η
∗
3 with η
∗
1 < 0 and η¯FG < η¯GH < 2η¯FG < η
∗
3 < 1.
From x(G) = x(H) √
λ2c2 − 4bcdηβ = 2acd
βη
− λc. (4.9)
Setting η = η∗1 or η = η
∗
3 , the right-hand term of (4.9) is negative. Thus x
(G) 6= x(H)
when η = η∗1 or η = η
∗
3 . From Y (η¯GH) = 0 and 0 < η¯GH < 2
ad
λβ
,
bβ3η¯3GH − acλβη¯GH + a2cd = 0
m
λ2c2 − 4bcdβη¯GH = 4a2c2d2β2η¯2
GH
− 4acdλc + λ2c2
m√
λ2c2 − 4bcdβη¯GH = 2acdβη¯GH − λc.
Thus, when η = η¯GH , (x
(G), y(G), z(G)) = (x(H), y(H), z(H)) and η¯FG < η¯GH < 1.
4. Note that
x(H) − a
ηβ
=
c(ληβ − 2ad) + ηβ
√
λ2c2 − 4bcdηβ
2cdηβ
.
When η ≥ 2ad
λβ
= 2η¯FG, x
(H) > a
ηβ
by (4.6). When η¯GH < η < 2η¯FG, Y (η) < 0
since this is a continuous function of η. Then,
−bβ3η3 + acλβη − a2cd > 0
m
η2β2(λ2c2 − 4bcdηβ) > (2acd − λcηβ)2
m
x(H) > a
ηβ
.
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Thus z(H) > 0 when η¯GH < η ≤ 1.

In what follows, let IF = [0, η¯FG), IG1 = (η¯FG, η¯GH), IG2 = (η
∗
3 , 1], and IH = (η¯GH , 1].
Theorem 3 Suppose Assumption 1 holds.
1. Point F is locally exponentially stable for η ∈ IF .
2. Point G is locally exponentially stable for η ∈ IG1 ∪ IG2.
3. Point H is locally exponentially stable for η ∈ IH .
Proof:
1. The Jacobian matrix of system (4.1)-(4.3) at the Point F is

−d −ηβ λ
d
0
0 ηβ λ
d
− a 0
0 0 −b

 ,
hence the stability is determined by the sign of the term ηβ λ
d
−a, which is negative
when η ∈ IF , hence the claim holds.
2. The Jacobian matrix of system (4.1)-(4.3) at the Point G is

−ηβ λ
a
−a 0
λβη−ad
a
0 −pλβη−ad
aηβ
0 0 −Y (η)
η3β3

 ,
where Y (η) is given in (4.8). Then the characteristic equation is s3+G1s
2+G2s+
G3 = 0 with
G1 = ηβ
λ
a
+
Y (η)
η3β3
,
G2 = (λβη − ad) + Y (η)
η2β2
λ
a
,
G3 = (λβη − ad)Y (η)
η3β3
.
From the proof of Lemma 1, Y (η) = 0 when η = η¯GH or η = η
∗
3 , and Y (η) > 0
when η¯FG ≤ η < η¯GH or η∗3 < η ≤ 1.
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Hence if η ∈ IG1 ∪ IG2, G1 and G3 are positive, and
G1G2 −G3 = ηβλ
a
(
λβη − ad+ Y (η)
η2β2
λ
a
+
Y (η)
η3β3
2
)
> 0.
Thus, when η ∈ IG1∪IG2, Point G is locally exponentially stable by Routh-Hurwitz
criterion.
3. The Jacobian matrix of system (4.1)-(4.3) at the Point H is

−d− ηβy(H) −ηβx(H) 0
ηβy(H) 0 −py(H)
2cx(H)y(H)z(H) cx(H)
2
z(H) 0

 ,
where x(H), y(H) and z(H) are from Table 4.1. Then the characteristic equation is
s3 +H1s
2 +H2s+H3 = 0, with
H1 =
λ
x(H)
,
H2 = (ηβx
(H) − a)b+ ηβ(λ− dx(H)),
H3 =
bλ
x(H)
(ηβx(H) − a)− 2pbηβy(H)z(H).
For η ∈ IH , H1 is positive and
H3 =
bλ
x(H)
(ηβx(H) − a)− 2pbηβy(H)z(H) = pbz
(H)
x(H)
(2dx(H) − λ) > 0,
because x(H) =
λc+
√
λ2c2−4bcdηβ
2cd >
λ
2d . Moreover, in this interval
H1H2 −H3 = λ
x(H)
ηβ(λ − dx(H)) + 2pbηβy(H)z(H) > 0,
since
x(H) − λ
d
=
−λc+
√
λ2c2 − 4bcdηβ
2cd
< 0.
Therefore, when η ∈ IH , Point H is locally exponentially stable by Routh-Hurwitz
criterion.

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4.3 Treatment by gradual reduction of drug dose
Assumption 2 The drug is so effective that
(1− ǫ∗)λβ
da
< 1. (4.10)
Theorem 4 Consider the system (4.1)-(4.3) and assume Assumptions 1 and 2 hold.
Then all trajectories X(t) with u = 1 converge to Point F.
Proof: As in the proof of Theorem 2, let V (t) = x(t) + y(t). Then, by (4.4), V˙ (t) =
λ− dx − ay − pzy ≤ λ − d(x + y) − (a − d)y ≤ λ − d(x + y) = λ − dV (t), which holds
for all t ≥ 0 due to the positive invariance of P.
If y(t) converges to zero, then the claim holds because of (4.1), (4.2), and (4.3).
Otherwise, V (t) becomes less than λ/d eventually since V˙ (t) < λ − dV (t). This in
turn implies that x(t) < λ/d in a finite time. Then equation (4.2) becomes
y˙ = y(ηβx− a− pz) ≤ −δy, (4.11)
for some δ > 0, because η < (da)/(λβ). Hence y(t) converges to zero, which is contra-
diction.
Since y(t) goes to zero, x(t) converges to λ/d by (4.1) and z(t) goes to zero by (4.3).

Now we state the treatment idea which is based on [42, Lemma 9.8] and consists of
two steps. In the first step we use full dosage (i.e., u = 1). Thus η is in the interval IF ,
and by Theorem 4 the state X(t) converges to Point F. In the second step, we slowly
reduce the dosage, so that the state X(t) follows the exponentially stable equilibrium,
Point G and then Point H. This may drive the state near Point H when η becomes 1
(i.e., u = 0).
Using Table 4.1 we define the exponentially stable points line (ESPL) χ(η) as
χ(η) =


Point F, η ∈ IF ,
Point G, η ∈ IG1,
Point H, η ∈ IH .
(4.12)
Note that Point G and H are functions of η whereas Point F is not. We regard the ESPL
not defined at η = η¯FG and η = η¯GH since we do not have proven exponential stability of
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Figure 4.1: 3 dimensional plot of the exponentially stable points line (ESPL) given in
(4.12). The case of η ∈ IF corresponds to Point F, (10, 0, 0).
λ d β a p c b x(0) y(0) z(0)
1 0.1 1 0.2 1 0.03 0.01 0.2 4.9 10−4
Table 4.2: Parameters and initial conditions for model (4.1)-(4.3).
any equilibrium point for these values of η. For additional analysis of the case η = η¯FG
and η = η¯GH , see [66].
Figure 4.1 shows the ESPL with the parameters of Table 4.2. Figure 4.2 displays the
result of the application of the GRDD with ǫ∗ = 0.99 and the initial condition which
corresponds to a serious status of AIDS, as presented in Table 4.2. The first and second
step take 50 days and 450 days, respectively. Figure 4.3 is a 3 dimensional plot based
on Figure 4.1 and Figure 4.2. The thick line and the thin line correspond to the ESPL
and the state trajectory, respectively. Note that the scale is not as in Figure 4.1. Figure
4.3 shows that the patient is driven to the LTNP status.
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Figure 4.2: Result of the application of the gradual reduction of drug dose (GRDD).
The unit of x and y is (100copies/µl).
Figure 4.3: 3 dimensional plot of the result of gradual reduction of drug dose (GRDD).
The thick line is the ESPL and the thin line is the state trajectory, which starts at the
point (0.2000, 4.9000, 0.0001) marked with ∗.
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4.4 Conclusion
In this chapter we have applied a new treatment scheme, known as GRDD, to the HIV
infection model in [40] exploiting the positivity property of the system and a bifurcation
analysis. It has been shown that, for any initial state, the state of the patient can be
steered to the LTNP status by the proposed treatment if the model parameters satisfy
specific assumptions. The results in this chapter are presented in [17].
In addition, the preliminary work for this chapter is published in [27], and its appli-
cations are included in [25], [26], and [24]. The formal analysis and proofs for the work
of the chapter are shown in [66] as well as [64].
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Chapter 5
Control method by activation of
the immune response
The purpose of this chapter is to derive a new drug scheduling methodology for HIV
patients on the basis of the properties of the immune system. The main idea stems from
a simple graphical analysis. In this chapter we do not provide a formal treatment of
the properties of the controlled system, but focus on the methodological and conceptual
aspects of the design. The results in this chapter are published in [21], [16], [19], and [18].
5.1 Analysis and control of HIV model with CTL-mediated
immune response
In this section we consider the model (2.1)-(2.5), namely
x˙ = λ− dx− ηβxy, (5.1)
y˙ = ηβxy − ay − p1z1y − p2z2y, (5.2)
z˙1 = c1z1y − b1z1, (5.3)
w˙ = c2xyw − c2qyw − b2w, (5.4)
z˙2 = c2qyw − hz2. (5.5)
For the clinical meaning of the states, see Table 2.1. The model (5.1)-(5.5) has five
equilibrium points, three of which are recalled here from Table 3.1:
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Point A:
x(A) =
λ
d
, y(A) = 0, z1
(A) = 0, w(A) = 0, z2
(A) = 0;
Point C:
x(C) =
λc1
dc1 + b1ηβ
, y(C) =
b1
c1
, z1
(C) =
ηβx(C) − a
p1
, w(C) = 0, z2
(C) = 0;
Point E:
y(E) =
c2(λ− dq)− b2ηβ −
√
[c2(λ− dq)− b2ηβ]2 − 4ηβc2qdb2
2ηβc2q
, x(E) =
λ
d+ ηβy(E)
,
z1
(E) = 0, w(E) =
hz2
(E)
c2qy(E)
, z2
(E) =
y(E)(c2ηβq − c2a) + b2ηβ
c2p2y(E)
;
Table 5.1: Equilibrium points of the model (5.1)-(5.5)
In this section we use the same system parameters of Chapter 3 (see Table 3.2),
whereas we use a different initial point. The initial point is one of those used in [82] as
indicated in Table 5.2. This point is in the vicinity of Point A, which represents a newly
infected patient1.
x(0) y(0) z1(0) w(0) z2(0)
10 0.01 0.01 0.01 0.01
Table 5.2: Initial condition for model (5.1)-(5.5). This initial condition is given in [82].
From the discussion in Section 3.2, we can regard model (5.1)-(5.5) as the inter-
connection of two subsystems: the infection dynamics and the immune system [15, 22].
The goal of the control in this chapter is to enhance immunity and this is equivalent to
boosting z1, w, and z2. Particularly, helper-dependent responses (i.e., w and z2) must
be enhanced in order to lead a HIV patient to the LTNP status (Point E), because the
w and z2 components of Point C are zero and those of Point E are positive and large.
In addition, since z2 depends upon w (see equation (5.5)), if w is increased, then z2 is
also increased.
Equation (5.4) can be written as w˙ = K(x, y)w where K(x, y) = c2xy − c2qy − b2.
1This point is also regarded as the status of a HIV patient that has been treated with HAART for a
long time [82].
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Figure 5.1: Graphical properties of the immune system enhancement in model (5.1)-
(5.5).
Note that K(x, y) depends upon the variables x and y of the infection dynamics, and
also note that the infection dynamics is directly affected by the drug. Accordingly we
can control w˙ indirectly via the input u.
Figure 5.1 shows some geometric properties of the function K(x, y) for the given
parameters in the (x, y) positive quadrant. The dotted line describes the setK(x, y) = 0.
Since K(x, y) > 0 above this line the immune term w increases when (x, y) belongs to
this region. The dashed line and the solid line describe the sets K(x, y) = 0.5 and
K(x, y) = 1, respectively. πE and πC correspond to the projection into the (x, y)-plane
of Point E and Point C, respectively. π0 indicates the projection into the (x, y)-plane of
the initial state.
The basic control idea is to force the patient state to be such that w˙(t) > 0 as long
as possible. In the case of model (5.1)-(5.5) this idea can be implemented by means of
the following control procedure.
5.1.1 The control procedure
Initialization: Select a positive number Ts. Ts denotes the sampling time for the
computation of the control input. Let w denote the immune term, K = c2xy− c2qy− b2
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the immune increasing factor, and the set K(x, y) ≥ 0 in the (x, y) positive orthant the
immune increasing region. XI is the initial condition of model (5.1)-(5.5).
STEP 1: Integrate model (5.1)-(5.5) with initial condition XI for Ts time instants
with full medication and with no medication. Let XF,fm and XF,nm be the values of the
state of the model (5.1)-(5.5) at the end of the integration period with full medication
and with no medication, respectively. Let πF,fm and πF,m be the projections of XF,fm
and XF,nm, respectively, on the (x, y) plane.
STEP 2: If πF,fm is not in the immune increasing region, then set u = 0.
If πF,fm is in the immune increasing region and πF,nm is not in the immune increasing
region, then set u = 1.
If both πF,nm and πF,fm are in the immune increasing region and the immune term of
XF,nm is not smaller than that of XF,fm, then set u = 0.
If both πF,nm and πF,fm are in the immune increasing region and the immune term of
XF,fm is greater than that of XF,nm, then set u = 1.
STEP 3: The input determined in STEP 2 is applied to the model (5.1)-(5.5) with
initial point XI for Ts time instants. Let XF be the values of the state at the end of the
integration period.
STEP 4: Set XI = XF and go to STEP 1.
Consider the set Ω of the positive orthant such that all initial conditions in Ω are
driven to the LTNP status by the proposed control procedure. The shape and size of the
set Ω depend upon the system’s parameters and the value of Ts. A simple estimate of Ω
will be computed in Subsection 5.1.2. For initial conditions outside Ω to be driven inside
Ω, it is necessary to apply a preliminary control action, for example full medication over
a sufficiently long period (which will be considered in the next chapters). Note that
the initial condition in Table 5.2, associated to a patient treated by long time HAART
therapy, belongs to the set Ω, as shown in Figure 5.2 and Figure 5.3.
Figure 5.2 shows the results of the application of the proposed control procedure
with Ts = 1 (day)
2. The control input becomes eventually zero3 and the patient state
converges to the LTNP status, namely to Point E which is (8.2255, 0.0216, 0, 1240,
2This assumes that HIV measurements are carried out from day to day. If we choose smaller Ts, then
the state trajectory can be controlled more minutely. This issue will be considered in the next chapters.
319 days are required for the control signal to reach zero in Figure 5.2.
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Figure 5.2: Results of the application of the control procedure in Section 5.1.1 to model
(5.1)-(5.5) with Ts = 1 (day). The unit of x and y is (100copies/µl).
Figure 5.3: The (x, y) trajectory resulting from the proposed control strategy. The
dotted line indicates the set K(x, y) = 0 and the solid line indicates the (x, y) trajectory.
The (x, y) trajectory stays within the immune increasing region, c2xy − c2qy − b2 ≥ 0,
and converges to Point E.
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Figure 5.4: Estimation of the set Ω with z1 = 0.01, w = 0.01, and z2 = 0.01. The “·”
and the “+” marks denote the projections of the initial points and of the final points in
the (x, y) plane, respectively.
8.0255) for the given parameters. The (x, y) trajectory is shown in Figure 5.3, which
shows that the (x, y) trajectory stays within the immune increasing region c2xy− c2qy−
b2 ≥ 0 for all t ≥ 0.
The proposed control strategy relies on the knowledge of the immune increasing
region, which depends upon system’s parameters. Note however that it is sufficient to
use a conservative estimate of the immune increasing region, hence rendering the control
strategy robust.
5.1.2 The set Ω
To estimate the set Ω we use computer simulations. In these simulations it is assumed
that z1(0) = 0.01, w(0) = 0.01 and z2(0) = 0.01, which means that the immune system
is hardly boosted. We simulate with pairs of initial points (x(0), y(0)) with x(0) and
y(0) taking values in the set {0.01, 1, 2, 3, · · · , 10}. All other conditions are as in the
previous subsection.
In Figure 5.4, the initial points are indicated with “·” marks in (x, y) plane. The
“+” marks denote the (x, y) states after the control process for 400 days. Figure 5.5
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Figure 5.5: Zoomed in version of Figure 5.4. All “+” marks from Figure 5.4 are shown
in this graph. The “+” marks belong to the region of attraction of Point E and belong
to the immune increasing region.
shows a zoomed in version of Figure 5.4. All considered initial states yield trajectories
which converge to the LTNP state, πE . Particularly the trajectory with x(0) = 10 and
y(0) = 0.01 is displayed in Figure 5.2 and Figure 5.3. The suggested control idea works
for all considered initial points.
5.2 Analysis and control of HIV model with two target cell
types
In this section we consider model (2.14)-(2.19) of Section 2.1.3, namely
x˙1 =λ1 − d1x1 − (1− ǫ1u1)k1vx1, (5.6)
x˙2 =λ2 − d2x2 − (1− fǫ1u1)k2vx2, (5.7)
y˙1 =(1− ǫ1u1)k1vx1 − δy1 −m1zy1, (5.8)
y˙2 =(1− fǫ1u1)k2vx2 − δy2 −m2zy2, (5.9)
v˙ =(1− ǫ2u2)NT δ(y1 + y2)− cv −A1(x1, x2, u1)v, (5.10)
z˙ =λE +
bE(y1 + y2)
(y1 + y2) +Kb
z − dE(y1 + y2)
(y1 + y2) +Kd
z − δEz, (5.11)
with A1(x1, x2, u1) = (1− ǫ1u1)ρ1k1x1 + (1− fǫ1u1)ρ2k2x2.
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We use the same system parameters and an initial point of [10], as indicated in Table
5.3. The model (5.6)-(5.11) with the given parameters has at least4 two asymptotically
stable equilibrium points, which correspond to the AIDS status and the LTNP status
[1, 10]. The initial point represents a patient immediately after the HIV infection.
λ1 d1 ǫ1 k1 λ2 d2 f k2 δ
10 0.01 0.7 8.0× 10−4 31.98 × 10−3 0.01 0.34 0.1 0.7
m1 m2 ǫ2 NT c ρ1 ρ2 λE bE
0.01 0.01 0.3 100 13 1 1 1.0× 10−3 0.3
Kb dE Kd δE T1(0) T2(0) T
∗
1 (0), T
∗
2 (0) V (0) E(0)
0.1 0.25 0.5 0.1 1000 3.198 0.0 0.001 0.01
Table 5.3: Parameters and initial conditions for model (5.6)-(5.10).
The dynamics of the CTL effector z (given in equation (5.11)) are explained in [12].
Equation (5.11) can be written as z˙ = λE +K(y)z, where
K(y) =
bEy
y +Kb
− dEy
y +Kd
− δE ,
with y = y1 + y2. The states y1 and y2 are determined by equations (5.8) and (5.9),
respectively and these two equations include the RTI therapy input term, u1. Conse-
quently z˙ is affected by the input u1. Figure 5.6 shows the graph of K = K(y) as a
function of y for the given system parameters. If K(y) is non-negative and λE is a pos-
itive constant, then z˙ > 0. Therefore the condition K(y) ≥ 0 implies that the patient’s
state is inside the immune increasing region. With the given parameters, K(y) = 0 when
y is either 0.0821 or 1.2178. Hence if y ∈ [0.0821, 1.2178] the immune system is boosted.
To apply the control methodology from Section 5.1 to model (5.6)-(5.10) we assume
that u1 = u2 = u because drug therapy with only one category
5 of anti-HIV drugs can
cause the emergence of drug-resistant strains of HIV [83]. The state z is regarded as the
immune term and K(y) is regarded as the immune increasing factor. With this definition
it is possible to apply directly the control steps proposed in Section 5.1. Similarly to
4In [1,10], it is only shown that two of the equilibria of model (5.6)-(5.11) are asymptotically stable
with the parameters of Table 5.3. Note that we do not need the stability of any other equilibrium points
for the discussion in this thesis.
5Note that the input terms u1 and u2 represent the antiviral effects from reverse transcriptase in-
hibitors (RTI) and protease inhibitors (PI), respectively.
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Figure 5.6: Graph of the function K(y). The function derived from (5.11) is K(y) =
bEy
y+Kb
− dEy
y+Kd
− δE with y = y1 + y2. The dotted line represents the set K(y) = 0. With
the given parameters, K(y) = 0 when y is either 0.0821 or 1.2178.
what discussed in Section 5.1 it is possible to estimate a subset such that all initial
conditions in this subset are driven to the LTNP state by the proposed control strategy.
Figure 5.7 shows the results of the application of the control procedure with Ts = 1.
The control input converges to zero and the patient states converges to the LTNP status,
given by (967.839, 0.621, 0.076, 0.006, 0.415, 353.108) [10]. The (x, y) trajectory is
displayed in the top graph of Figure 5.8, where x = x1 + x2. π0 in the graph represents
the initial point in the (x, y) plane, and πLTNP and πAIDS denote the LTNP status
and the AIDS status in the (x, y) plane, respectively. These two points are locally
asymptotically stable [10]. πFM indicates the point which is asymptotically stable when
u = 1.
The bottom graph of Figure 5.8, which is a zoomed version of the top graph, provides
an explanation of the control mechanism. In particular the shaded region is the region
where the immune term z is enhanced. In the first two days of simulation the control
input is zero because the patient state cannot enter the shaded area regardless of the
input. As a result the patient state converges to πAIDS (which is outside the area of
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Figure 5.7: The results of the control procedure applied to model (5.6)-(5.10) with
Ts = 1. The unit of x and y is (copies/µl). (Note the different time axis in the bottom
left graph.)
Figure 5.8: (x, y) graphs from Figure 5.7.
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the bottom graph) and penetrates into the shaded area only in the third day. When the
initial state is in the shaded area and u = 0, the resulting trajectory is a counterclockwise
spiral converging to πAIDS. On the other hand if u = 1 and the state is in region A,
then the trajectory is a counterclockwise spiral converging to πFM , whereas if u = 1 and
the state is in region B, then the trajectory is a clockwise spiral and converges to πFM .
This implies that if the trajectory reaches the shaded area, where the immune term is
enhanced, then there is a switching input sequence which forces the state to remain in
the shaded area, provided Ts is sufficiently small. This behaviour is clearly illustrated
in the bottom graph of Figure 5.8.
5.3 Analysis and control of disease dynamic model
In this section we show that the control methodology proposed in Section 5.1 is applicable
to the model (2.24)-(2.27) discussed in Section 2.1.5, namely
x˙1 = (a11 − a12x3)x1 + b1u1, (5.12)
x˙2 = a21(x4)a22x1(t− τ)x3(t− τ)− a23(x2 − x2∗) + b2u2, (5.13)
x˙3 = a31x2 − (a32 + a33x1)x3 + b3u3, (5.14)
x˙4 = a41x1 − a42x4 + b4u4. (5.15)
We use the same system parameters and one of the initial conditions of [67, 69], as
indicated in Table 5.4. The initial condition corresponds to a patient who would be led
to fatal damage of the body without treatment.
a11 a12 a22 a23 a31 a32 a33 a41 a42 b1
1 1 3 1 1 1.5 0.5 0.5 1 −1
b2 b3 b4 τ x2
∗ x1(0) x2(0) x3(0) x4(0)
1 1 −1 0 2 3 2 4/3 0
Table 5.4: Parameters and initial conditions for model (5.12)-(5.15).
The function a21(x4), which describes the immune deficiency effect caused by the
damage of the organ, is selected as in [69], namely
a21(x4) =

 cos πx4, if 0 ≤ x4 ≤ 0.5,0, if 0.5 < x4. (5.16)
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Figure 5.9: The results of the application of the control procedure to model (5.12)-(5.15)
for 100 days with Ts = 0.1. The control method successfully suppresses the pathogen x1
in a short period.
In [67–69] the time unit is not specified and simulations are carried for 10 time units.
With the given initial state the patient’s organ becomes deadly damaged after 4 time
units [67–69]. We assume that 1 time unit in model (5.12)-(5.15) is 10 days and we set
Ts = 0.1, which corresponds to 1 day, to implement the control strategy of Section 5.1.
Consequently we simulate model (5.12)-(5.15) for 100 days. Note that without treatment
the disease would result in a fatally damaged organ after 40 days.
To apply the control methodology proposed in Section 5.1 to model (5.12)-(5.15) we
assume u2 = u3 = u4 = 0, hence u1 is the only control input. This is motivated by the
observation that the antiviral drug input in model (5.1)-(5.5) corresponds to the antigen
killer u1 in model (5.12)-(5.15). In addition we regard the state x2 as the immune term
and the function a21(x4)a22x1(t− τ)x3(t− τ) as the immune increasing factor K, which
is a function of x1, x3, and a21(x4), when τ = 0. Thus K(x1, x3, a21(x4)) ≥ 0 is the
immune increasing space of the model6. With these assumptions it is possible to apply
6We call K(x1, x3, a21(x4)) ≥ 0 the immune increasing space, instead of immune increasing region,
because the immune increasing factor K is a function of three variables.
66
Figure 5.10: The (x1, x3, a21(x4)) trajectory from Figure 5.9. π0 and π100 indicate the
projections of the initial and final points into the (x1, x3, a21(x4)) space, respectively.
the control strategy developed for model (5.1)-(5.5) to the model (5.12)-(5.15).
Note, however that, as x1 and x3 are positive, a22 = 3, and a21(x4) is non-negative,
by (5.16), the trajectory always stays in the immune increasing space. As a result STEP
2 of the procedure has to be replaced by the following step.
STEP 2∗: The control input is the one that maximizes x2 at the end of the inte-
gration period.
Figure 5.9 shows the results of the application of the proposed control procedure
for 100 days. The procedure, unlike what proposed in [67–69] (where optimal control
tools are used), provides either full dosage or no dosage of medication for each day and
successfully suppresses the pathogen x1 in a short period. The (x1, x3, a21(x4)) trajectory
obtained from the control procedure is displayed in Figure 5.10.
5.4 Analysis and control of HIV model with two immune
response types
In this section we evaluate the control idea by applying it to an alternative HIV dynamic
system, which shows a tristability property. To the best of our knowledge, this is the first
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study on drug scheduling for a tristable HIV model. We consider the model (2.20)-(2.23)
in Section 2.1.4, namely
x˙ = λ− dxx− ηβyxN, (5.17)
x˙1 = λH +
αyx1
γ1 + y
− ǫx21 − ηβHyx1N, (5.18)
x˙2 = λH +
αyx2
γ2 + y
− ǫx22 − ηβHyx2N, (5.19)
y˙ = ηy[βx+ βHx1 + βHx2]N − dyy −Ky, (5.20)
where γ2 > γ1, K = K(x1, x2) = k1x1 + k2x2, and
N = N(x1, x2) =
1
1 + n1x1 + n2x2
.
We use the same system parameters of [6], as indicated in Table 5.5.
λ λH dx dy α β βH γ1 γ2 ǫ
2 10−7 0.05 0.2 0.3 0.03 0.03 2 6 0.05
k1 k2 n1 n2 ǫ
∗ x(0) x1(0) x2(0) y(0)
0.1 0 0 2 0.8 6.6671 0.0001 0.0001 8.3327
Table 5.5: Parameters and initial conditions for model (5.17)-(5.20).
With these parameters model (5.17)-(5.20) is a tristable system [6] when u = 0. To
highlight this property three trajectories of the systems are displayed in Figure 5.11.
The three initial conditions in Figure 5.11 are (40, 5, 5, 1), (0.01, 0.01, 0.01, 10), and
(10, 1, 0.01, 6). We integrate model (5.17)-(5.20) with u = 0 from these initial conditions
for 1, 000 days, and obtain the three points :
Point P : (30.5919, 2.0279, 0.7433, 1.2737),
Point Q : ( 6.6671, 0.0000, 0.0000, 8.3328),
Point R : ( 9.0522, 1.0225, 0.0000, 5.6985).
Figure 5.11 shows that each trajectory converges to one of these points. Point Q implies
the status of a patient for whom HIV dominates, which is locally stable with the given
parameters. Point P describes the LTNP, i.e. a patient who is infected with HIV but
does not progress to AIDS. With the given parameters Point P is also locally stable. At
Point P, the number of infected cells (the y component) is maintained very low, while the
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Figure 5.11: State histories of model (5.17)-(5.20) with input u = 0 from the initial
state (40, 5, 5, 1) (top graphs), (0.01, 0.01, 0.01, 10) (middle graphs), (10, 1, 0.01, 6)
(bottom graphs). x(t) and x1(t) are represented by solid lines while y(t) and x2(t) are
represented by dotted lines.
numbers of the HIV-specific CD4 T-cells (the x1 and x2 components) are large, which
is desired. Finally Point R can be interpreted as a substitution status for the LTNP,
which will be discussed in Sections 5.4.2. The main goal of controlled drug scheduling
is to bring the state of a patient to within a small neighbourhood of the LTNP status,
Point P.
The initial state considered in this section is shown in Table 5.5, which represents a
patient with AIDS, in the vicinity of Point Q. Figure 5.12 shows the simulation result of
the withdrawal of drugs after full-dosage treatment for 500 days with this initial point.
Regardless of the treatment, the infected cells (y state) re-emerge to pre-treatment levels
and the immune response (x1 and x2 states) are not excited after the cessation of drugs.
Hence immunological control of the HIV in the absence of the drug is not achieved and
a systematic drug scheduling is needed for the HIV patient to be driven into the region
of attraction of the LTNP status.
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Figure 5.12: Result of the cessation of drugs after 500 days of treatment. Although
the infected cells (y) seem to be eradicated during the treatment, they re-emerge to
pre-treatment levels when the drugs are stopped.
5.4.1 Modification of the control procedure
Exploiting the ideas introduced in Chapter 3 we regard model (5.17)-(5.20) as the in-
terconnection of two subsystems: the infection dynamics and the immune system (see
Figure 5.13). The infection dynamics are described by equations (5.17) and (5.20), while
the immune system is represented by equations (5.18) and (5.19). The goal of the control
is to enhance immunity, and this is equivalent to boosting x1 and x2. To lead a HIV
patient to the LTNP status (Point P), the HIV specific immune response (i.e., x1 and
x2) must be enhanced because the x1 and x2 components of Point Q are zero and those
of Point P are positive and large. Therefore we must increase the x1 and x2 terms by
controlled medication scheduling.
Equation (5.18) can be written as
x˙1 = λH +K1(x1, x2, y, u)x1,
where
K1(x1, x2, y, u) =
αy
γ2 + y
− ǫx1 − (1− ǫ∗u)βHyN1(x1, x2),
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Figure 5.13: Interconnection between the infection dynamics and the immune system in
model (5.17)-(5.20). Note that the input u is applied to both subsystems.
with N1(x1, x2) =
1
1+n1x1+n2x2
. On the other hand equation (5.19) can be written as
x˙2 = λH +K2(x2, y, u)x2,
where
K2(x2, y, u) =
αy
γ2 + y
− ǫx2 − (1− ǫ∗u)βHyN2(x2),
with N2(x2) =
1
1+n2x2
. In this section we consider the case7 with n1 = 0 and k2 = 0.
Figure 5.14 shows some geometric properties of the function K1(x1, x2, y, u) for the
given parameters and for x2 = 0, in the (x1, y) positive orthant. The dotted lines describe
the sets in which K1(x1, 0, y, 0) = 0, K1(x1, 0, y, 0) = 0.02, and K1(x1, 0, y, 0) = 0.04,
respectively. The solid lines depict the sets in which K1(x1, 0, y, 1) = 0, K1(x1, 0, y, 1)
= 0.05, and K1(x1, 0, y, 1) = 0.1, respectively. These graphs allow to conclude, for
example, that if x2 is sufficiently small and the point (x1, y) is placed into the set in
which K1(x1, 0, y, 0) = 0 and x1 > 0, then the state x1 increases when u = 0. π˜P , π˜Q,
and π˜R correspond to the projection into the (x1, y)-plane of Point P, Point Q, and Point
R, respectively. Note that π˜Q and π˜R are located in the set in which K1(x1, 0, y, 0) = 0,
while π˜P is not.
Figure 5.15 shows some geometric properties of the function K2(x2, y, u) for the
given parameters in the (x2, y) positive quadrant. The dotted lines indicate the sets
in which K2(x2, y, 0) = 0, K2(x2, y, 0) = 0.02, and K2(x2, y, 0) = 0.04, respectively.
The solid lines represent the sets in which K2(x2, y, 1) = 0, K2(x2, y, 1) = 0.05, and
K2(x2, y, 1) = 0.1, respectively. These graphs allow to conclude, for example, that if the
point (x2, y) is such that K2(x2, y, 0) = 0, then the state x2 increases when u = 0 by
7In [6], this case is described as x1 is lytic and x2 is non-lytic. Lytic immune response kills infected
cells, whereas nonlytic immune response inhibits viral replication via soluble mediators [74].
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Figure 5.14: Properties of the function K1(x1, x2, y, u).
(5.19) and λH > 0. πP , πQ, and πR correspond to the projection into the (x2, y)-plane
of Point P, Point Q, and Point R, respectively.
Note that only the Point P (i.e., the LTNP) has a positive x2 component among the
three steady states, and that K2(x2, y, 0) depends upon the variables x2 and y, which
are directly affected by the drug from (5.19) and (5.20). Accordingly, we can control
x˙2 indirectly via the input u. The basic control idea is therefore to force the state to
be such that K2(x2, y, u) ≥ 0 (which implies x˙2(t) > 0) as long as possible. In the case
of model (5.17)-(5.20) this idea can be implemented by means of the following control
procedure.
The control procedure
Initialisation: Select a positive number Ts. Ts denotes the sampling time for the
computation of the control input. Let x2 denote the immune term, K2(x2, y, u) the
immune increasing factor, the set in the (x2, y) plane in which K2(x2, y, 0) ≥ 0 the
immune increasing region for u = 0, the set in the (x2, y) plane in which K2(x2, y, 1) ≥ 0
the immune increasing region for u = 1. XI is the initial condition of model (5.17)-(5.20).
STEP 1: Integrate model (5.17)-(5.20) with initial condition XI for Ts with full
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Figure 5.15: Properties of the function K2(x2, y, u).
medication and with no medication. Let XF,fm and XF,nm be the values of the state
of the model (5.17)-(5.20) at the end of the integration period with full medication and
with no medication, respectively. Let πF,fm and πF,nm be the projections of XF,fm and
XF,nm, respectively, on the (x2, y) plane.
STEP 2: If πF,nm is not in the immune increasing region for u = 0, then set u = 1.
Otherwise set u = 0.
STEP 3: The input determined in STEP 2 is applied to the model (5.17)-(5.20)
with initial pointXI for Ts. Let XF be the value of the state at the end of the integration
period.
STEP 4: Set XI = XF and go to STEP 1.
5.4.2 Simulations and remarks
Figure 5.16 shows the results of the application of the proposed control procedure with
Ts = 1 (day). The control input becomes eventually zero and the patient state converges
to the LTNP status, namely to Point P. The resulting (x2, y) trajectory is displayed in
the top graph of Figure 5.18, which shows that the (x2, y) trajectory stays within the
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Figure 5.16: Results of the application of the control procedure in Subsection 5.4.1 to
model (5.17)-(5.20) with Ts = 1 (day).
immune increasing region for u = 0.
While the given initial state XI is successfully driven to the LTNP status we now
investigate an alternative strategy by which XI is driven to Point R (the importance
of this alternative control goal will be discussed later in this section). To this end we
consider the following step, which replaces STEP 2 of the control procedure.
STEP 2′: If πF,fm is not in the immune increasing region for u = 0, then set u = 1.
Otherwise set u = 0.
From the initial point XI , full dosage (i.e., u = 1) forces the trajectories to move
towards the lower-right of the (x1, y)-plane and of the (x2, y)-plane by (5.18), (5.19),
and (5.20). No medication (i.e., u = 0) drives the trajectories towards the upper-left
of those planes. Therefore the input decision in STEP 2′ yields on-off switches of u
without boosting the state x2. Note that on-off input switches enhance the state x1 in
the vicinity of Point Q, as we can see from Figure 5.14. Thus the control procedure with
STEP 2′ is such that the initial point XI reaches Point R, while the control procedure
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Figure 5.17: Results of the application of the alternative control procedure with STEP
2′ to model (5.17)-(5.20) with Ts = 1 (day).
with STEP 2 drives the initial state to Point P by enhancing both x1 and x2.
Figure 5.17 shows the results of the application of the alternative procedure with
Ts = 1 (day). The control input becomes eventually zero and the patient state converges
to Point R. The (x2, y) trajectory is displayed in the bottom graph of Figure 5.18, which
shows that the (x2, y) trajectory stays outside the immune increasing region for u = 0.
In Figure 5.18 the dotted lines indicate the sets in which K2(x2, y, 0) = 0, K2(x2, y, 0)
= 0.02, and K2(x2, y, 0) = 0.04, respectively. The solid lines describe the (x2, y) tra-
jectories. Note that the (x2, y) trajectories starts from XI , which is close to πQ. The
trajectory of the top graph converges towards πP , while that of the bottom graph con-
verges towards πR.
We complete this section with some remarks.
1. One of the most difficult problems in HIV treatment is the emergence of HIV
mutation [37]. If HIV mutates to escape from the LTNP status (Point P in this
section) then this virus cannot be suppressed by the human immune response [79].
This is the reason why we investigate the control method of STEP 2′.
75
Figure 5.18: The (x2, y) trajectories resulting from the proposed control strategies. In
the top graph the (x2, y) trajectory stays within the immune increasing region for u = 0,
while we can see that the trajectory of the bottom graph stays outside the region. (Note
the different scales.)
If we drive the state to Point R and again to Point P, then the emergence of HIV
mutants against both x1 and x2 can be postponed as long as the state remains in
the neighbourhood of Point R. This is because the level of x2 is sufficiently low in
the vicinity of Point R and the mutational escape of HIV from x2 requires a certain
level of x2 [35]. Note that we deal with a model having three stable steady states,
but the more complicated models with n steady-states in [4, 40] can be studied
similarly.
2. To drive the patient status into the LTNP we can consider the GRDD scheduling
scheme, introduced in Chapter 4. We have applied the GRDD scheme to model
(5.17)-(5.20) with the initial state in Table 5.5. Figure 5.19 shows the result. We
see that the state is successfully driven to the LTNP status, Point P. However the
current scheme of GRDD cannot drive the state towards Point R.
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Figure 5.19: Result of GRDD application to model (5.17)-(5.20).
5.5 Conclusion
We have provided a unified control methodology for drug scheduling for disease dynamics
and have shown its applicability, by means of computer simulations, for different disease
models. The method relies on the intuitive idea that the control action has to boost
the immune system and it is based on a simple graphical analysis of the immune system
model. Our model-based study suggests that applying the proposed treatment in the real
world could lead to an immune control of HIV if the model is close to the actual immune
mechanism. Note that the proposed scheme serves as a guideline of drug planning rather
than a ready-to-use clinical treatment.
The control method is appropriate for HIV/AIDS cases. Figure 5.20 shows the
situation in HIV/AIDS treatment. The HIV antiviral drug produces an effect on the
levels of uninfected and infected HIV target cells. HIV target cells are key component
of the human immune system, and the dynamics of the immune system are related with
the populations of uninfected and infected HIV target cells. Therefore we can control
the drug dosage in order to maximize the action of the immune system in HIV/AIDS
models via the levels of uninfected and infected HIV target cells.
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Figure 5.20: The relations between drug input, HIV target cell, and the immune system
dynamics in HIV/AIDS treatment.
The results in this chapter are published in [21], [16], [19], and [18]. In conclusion
we comment on further ideas which may be considered to advance the present results.
1. The simulations in Section 5.1 and Section 5.3 initiate drug therapy on the sec-
ond and the fifth day, respectively, because no medication increases the immune
response faster than full medication in the beginning of the treatment. In the sim-
ulation of Section 5.2 the medication initiates on the third day because we must
wait the patient state to enter the immune increasing region. The long delay of
treatment initiation in [47], where the medication initiates at ninth year, is due to
the maximization of the efficacy of drug dose. For the problem of the decision of
therapy initiation, a theoretic controllability analysis is given in [41].
2. The immune system’s models in this chapter have different properties. For ex-
ample, Figure 5.1 and Figure 5.8 show different shapes of the immune increasing
regions in the plane identified by the levels of uninfected and infected HIV target
cell. The boundary in Figure 5.1 is a curved line, whereas that in Figure 5.8 is
composed of two straight lines. Accordingly the control results are not comparable
because the control steps are dependent on the immune increasing region, hence
on the model of the immune system.
3. In this chapter we use a constant Ts. However, a variable Ts can be used to
enhance further the immune system. For example, if we use a sufficiently small Ts
in Section 5.1, the (x, y) trajectory in Figure 5.3 would show smaller swings. In the
meanwhile we can divide the HIV therapy into two stages, first we make the patient
state enter the immune increasing region and then enhance the immune system as
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much as possible in the second stage. In this case we can use a comparatively large
constant Ts in the first stage and a variable Ts in the second stage.
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Chapter 6
Output feedback control in HIV
dynamics
The motivation of the research in this chapter comes from the drug scheduling methodol-
ogy for HIV patients in Chapter 5. The main idea, which stems from a simple graphical
analysis, has been conceptually introduced in Chapter 5, and in turn leads to the design
of a feedback control strategy in this chapter. In this chapter we justify the idea from a
mathematical perspective and provide some formal properties of the resulting controlled
system. The works in this chapter are included in [23] and [18].
6.1 Description of output feedback control
Consider model (2.1)-(2.5) of Section 2.1.1, which is also discussed in Chapter 3 and
Section 5.1, namely
x˙ = λ− dx− ηβxy, (6.1)
y˙ = ηβxy − ay − p1z1y − p2z2y, (6.2)
z˙1 = c1z1y − b1z1, (6.3)
w˙ = c2xyw − c2qyw − b2w, (6.4)
z˙2 = c2qyw − hz2. (6.5)
In this chapter we use the same system parameters of Chapter 3 and Section 5.1 as
nominal parameters (see Table 3.2). The model (6.1)-(6.5) has five equilibrium points,
80
three of which are recalled from Table 3.1, for convenience:
Point A:
x(A) =
λ
d
, y(A) = 0, z1
(A) = 0, w(A) = 0, z2
(A) = 0;
Point C:
x(C) =
λc1
dc1 + b1ηβ
, y(C) =
b1
c1
, z1
(C) =
ηβx(C) − a
p1
, w(C) = 0, z2
(C) = 0;
Point E:
y(E) =
θ(η)−√θ(η)2 − 4ηβc2qdb2
2ηβc2q
, x(E) =
λ
d+ ηβy(E)
,
z1
(E) = 0, w(E) =
hz2
(E)
c2qy(E)
, z2
(E) =
y(E)(c2ηβq − c2a) + b2ηβ
c2p2y(E)
;
where θ(η) = c2(λ− dq)− b2ηβ.
The initial point for the simulations in this chapter is identical to the initial point of
Section 5.1, that is, x(0) = 10, y(0) = 0.01, z1(0) = 0.01, w(0) = 0.01, and z2(0) = 0.01
(see Table 5.2) unless it is explicitly indicated. From the discussion in Section 3.2, we
can regard model (6.1)-(6.5) as the interconnection of two subsystems: the infection
dynamics and the immune system. The infection dynamics are described by equations
(6.1) and (6.2) and the immune system is described by equations (6.3)-(6.5). The goal of
the control is to enhance immunity. Then we must increase w by controlled medication
scheduling as discussed in Section 5.1, and we recall that equation (6.4) can be written
as w˙ = K(x, y)w, where K(x, y) = c2xy − c2qy − b2. Thus we can control the growth of
w, indirectly, via the input u. For some geometric properties of the function K(x, y) for
the given parameters see Figure 5.1 in Section 5.1.
In this section we propose a control strategy that requires only partial state infor-
mation. The states x and y are considered as output of the infection dynamics and
input of the immune system. These states are also regarded as the measured1 output
of the model (6.1)-(6.5). Thus the output feedback controller uses the states x and y as
controller input. A schematic diagram of the closed loop system is depicted in Figure
1The states x and y are measurable with experimental environment as discussed in Section 2.2. In
addition these states can be theoretically observed using Riccati equation-based estimator [10].
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Figure 6.1: Diagram describing the interconnections of the infection dynamics, the im-
mune system, and the controller.
6.1 and the control procedure is described in the following steps2.
Initialization: Select a positive number Ti. Ti denotes the period of full medication
preceding the application of the proposed control law and driving the state to Point A.
Let L1 = L1(x, y) = y − yκ and L2 = L2(x, y) = y − (x − q) where3 y(E) < yκ ≤ y(C).
XI is the initial condition of model (6.1)-(6.5).
STEP 1: (Preliminary Control Action)
Apply u = 1 for Ti time instants.
STEP 2: (The Control Law)
If L1 < 0 and L2 < 0, then u = 0. Otherwise, u = 1
4.
The preliminary control action is justified by the discussion in Section 5.5. The con-
trol law in STEP 2 corresponds to the control procedure of Section 5.1 for a sufficiently
small Ts and a different immune increasing region given by the conditions L1 < 0 and
L2 < 0.
Figure 6.2 shows the results of the application of the feedback control procedure
with yκ = b1/c1. In the simulation STEP 1 is unnecessary since the initial point (x(0),
2This control procedure stems from the discussion in Section 5.5.
3The property y(E) < y(C) will be proven in Lemma 3.
4Note that the output feedback is only used to decide the timing of u, not the magnitude of the u.
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Figure 6.2: Results of the application of the output feedback control scheme to model
(6.1)-(6.5) with yκ = b1/c1. The unit of x and y is (100copies/µl). Note the different
time scales.
y(0), z1(0), w(0), z2(0)) = (10, 0.01, 0.01, 0.01, 0.01) is sufficiently close to Point A.
The control input becomes eventually zero and the patient state converges to the LTNP
status, i.e., to Point E. The resulting (x, y) trajectory is displayed in Figure 6.3, which
shows that the (x, y) trajectory stays within the set defined by L1 < 0 and L2 < 0.
Note that the virus level (i.e., y) is restricted by the condition L1 < 0. This condition
prevents the state from progressing towards Point C. On the other hand the condition
L2 < 0 renders the increase of w locally optimised, see Subsection 6.2.5 for additional
discussion.
6.1.1 Examples of applications of the output feedback control
In this subsection we discuss further examples of applications of the output feedback
control, which will be discussed in Chapter 7. Particularly the initial point used in these
examples is identical to one of those used in [83], as indicated in Table 6.1. This point
is in the vicinity of Point A, which represents a newly infected patient.
Now we consider the trapezoidal set τ(yκ) defined by the inequalities y > 0, y < x−q,
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Figure 6.3: The (x, y) trajectory resulting from the output feedback control strategy.
The dotted line and the solid line indicate the set K(x, y) = 0 and the (x, y) trajectory,
respectively. The dashed line and the dash-dotted line represent the sets L1 = 0 with
yκ = b1/c1 and L2 = 0, respectively.
x + y < λ
d
+ ǫ, and y < yκ, where ǫ is any small positive number. The conditions
y(E) < yκ ≤ y(C) in the Initialization step guarantee that Point E and Point C are
located inside and outside the set τ(yκ), respectively.
x(0) y(0) z1(0) w(0) z2(0)
10 0.1 0.1 0.1 0.1
Table 6.1: Initial condition for model (6.1)-(6.5). This initial condition is given in [83].
Figure 6.4 shows the results of the application of the output feedback control with
yκ = 0.5 and Ti = 20. In STEP 1 the state moves sufficiently close to Point A and enters
the set τ . The control input becomes eventually zero and the patient state converges
to the LTNP status, i.e., to Point E. The top graph in Figure 6.4 shows that the (x, y)
trajectory stays within the set τ , which is the area enclosed by the dotted line.
Figure 6.5 shows the result of the same control scheme applied using a sample-and-
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Figure 6.4: Results of the application of the control procedure of Section 6.1 to model
(6.1)-(6.5).
Figure 6.5: Results of the application of the control procedure of Section 6.1 with a
sample-and-hold device of fixed sampling period. The sample period is 0.25 (day).
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Figure 6.6: Results of the application of the control procedure of Section 6.1 with a
sample-and-hold device with non constant sampling period. We assign 0.25 (day) sam-
pling period in the interval [20, 28), 1 (day) in the interval [28, 35), and 7 (day) in the
interval [35, 200]. In the top graph πC corresponds to the projection into the (x, y) plane
of Point C, and the dash-dotted line indicates the set y = y(C) = b1/c1.
hold device. The sample period Th is 0.25 (day). A sufficiently small Th
5 guarantees
that the (x, y) trajectory is such that y(t) < b1
c1
with yκ ≤ b1c1 because the control method
forces the state to stay inside the set τ (this fact will be proven in Subsection 6.2.3).
In clinical terms, the control example in Figure 6.5 implies four HIV measurements
in a day, which means the patient’s blood must be sampled every 6 hours. This is hard to
achieve practically. However this frequent sampling is not needed in all the time interval
[20, 200]. In other words we need a 0.25 (day) sampling period only for the first few
days in order for the HIV patient to be driven into the region of attraction of the LTNP.
For example, if we assign 0.25 (day) sampling period in the interval [20, 28), 1 (day) in
5This Th does not have the same meaning of the Ts in Section 5.1. In this section the control decision
is made at the current moment and the decision is held for Th, while in Section 5.1 the control decision
is made by predicting in Ts. Nonetheless, the resulting control actions are essentially the same because
these methods force the state to stay inside the set τ .
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the interval [28, 35), and 7 (day) in the interval [35, 200], then the immune system of
the patient is boosted enough to be in the region of attraction of LTNP. This result is
presented in Figure 6.6.
6.2 Analysis of the controlled HIV model
6.2.1 Basic analysis of the HIV model
Let X := [x, y, z1, w, z2]
T and let U denote the set of measurable functions with values in
the set [0, 1]. Note that the input η(·) of interest belongs to U . Finally let P = [0,∞)5.
Assumption 3 The parameters of the model (6.1)-(6.5) are positive and such that
d < a, (6.6)
β >
a
q
, (6.7)
λ > aq, (6.8)
b1
c1
> max
{
λ
2βq
,
1
2
(
λ
a
− q
)}
, (6.9)
b2
c2
< min
{
(
√
λ−√dq)2
β
,
1
4
(
λ
a
− q
)2
,
(
a− d
β
)2}
, (6.10)
(1− ǫ∗)β < min
{
ad
λ
,
(a− d)c1
2b1
}
. (6.11)
Although Assumption 3 is technically designed to subsequent analysis of this chapter
and the model parameters are normalized so the state variables do not represent actual
data, Assumption 3 can be justified by previous works in the literature on HIV dynamics
such as [54,75,83], as seen in what follows.
Inequality (6.6) implies that the decay rate of the uninfected cells is smaller than
that of the infected cells [54]. Inequality (6.7) gives a lower-bound for β. If the rate
of viral replication β is below a threshold, then an effective CTL response is always
established [75]. Hence, for very small β, the LTNP status is automatically achieved,
and the patient needs not be treated. However this is apparently not the case for most
AIDS patients. A quantitative lower-bound for β is not provided in [75]: the condition
(6.7) could be regarded as such a bound.
Inequality (6.8) requires that the differentiation of CTL precursor into helper-dependent
CTL occurs slowly. Combining (6.8) with (6.6) we obtain λ > dq, which is essential for
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the existence of the LTNP equilibrium. To see this, suppose that q ≥ λ
d
. Then, because
x ≤ λ
d
+ ǫ after a certain time (see the proof of Theorem 5), it follows from (6.4) that
w˙ ≤ c2(λ
d
)yw − c2qyw − b2w ≤ −b2w < 0,
for w 6= 0, which implies the extinction of CTL precursors and no treatment can induce
the drug-free immune control of HIV.
In (6.9), b1/c1 is assumed to be lower-bounded. Note that y
(C) = b1/c1, i.e., the y
level of the status of AIDS. Thus (6.9) implies that the disease status is seriously fatal
to the human body, which is consistent with the current outbreak of AIDS.
Regarding inequality (6.10), it is noted that if the immune responsiveness c2 lies
below a threshold, treatment cannot result in the establishment of CTL memory [75].
While any formula for such a threshold is not presented in [75], the condition (6.10)
might be understood as a possible lower bound for the immune responsiveness.
Inequality (6.11) means that highly effective drug treatment is available for HIV
patients. In the thesis we do not consider the drug-resistant case associated to HIV
evolution and we suppose that the virus level of the patient can be suppressed by drug
treatment. Inequality (6.11) requires a strongly effective drug and the mathematical
analysis in this chapter is based on this assumption. Note that the value of ǫ∗ from [83]
is such that inequality (6.11) does not hold. This value of ǫ∗ is nevertheless used in
simulations to highlight the robustness of the proposed methodology.
Lemma 2 Consider the model (6.1)-(6.5). Suppose Assumption 3 holds. Then y(E) is
well-defined and positive for u = 0.
Proof: If u = 0, then η = 1 and
y(E) =
θ(1)−√θ(1)2 − 4βc2qdb2
2βc2q
,
where θ(η) = c2(λ− dq)− b2ηβ. From (6.6), (6.10), and (6.8), θ(1) and θ(1)2− 4βc2qdb2
are positive. Also θ(1) −√θ(1)2 − 4βc2qdb2 > 0 because all parameters are positive.
Thus y(E) is well-defined and positive for u = 0. 
Lemma 3 Consider the model (6.1)-(6.5). Suppose Assumption 3 holds. Then y(E) <
y(C) for u = 0.
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Proof: From (6.9),
y(C) =
b1
c1
>
λ
2βq
=
c2λ
2βc2q
>
θ(1)
2βc2q
>
θ(1)−√θ(1)2 − 4βc2qdb2
2βc2q
= y(E),
where, as above, θ(η) = c2(λ− dq)− b2ηβ. 
Theorem 5 Consider the model (6.1)-(6.5). Suppose Assumption 3 holds and u(t) = 1
for all t ≥ 0. Then all trajectories with initial condition X(0) ∈ P converge to Point A.
Proof: Let V (t) = x(t) + y(t). By (6.6), V˙ (t) = λ − dx − ay − p1z1y − p2z2y ≤
λ − d(x + y) = λ − dV (t), which holds for all t ≥ 0 due to the positive invariance of
P. Then [0, λ
d
] is an attractive region for V (t). This implies that lim supt→∞ V (t) ≤ λd ,
which in turn implies that x(t) ≤ λ
d
+ ǫ for all ǫ > 0 and for all t ≥ tǫ for some tǫ > 0
(because x(t) and y(t) are both positive). Then equation (6.2) becomes
y˙ = y((1− ǫ∗)βx− a− p1z1 − p2z2) ≤ −δy,
for some δ, which is positive by equation (6.11). Hence, it follows that y(t) converges to
zero. Since y(t) goes to zero, x(t) converges to λ/d by (6.1). Then all other states (z1,
w, and z2) go to zero by equations (6.3)-(6.5). 
6.2.2 Properties of the immune increasing factor K
Now recall that K(x, y), defined as K(x, y) = c2xy − c2qy − b2, denotes the immune
increasing factor and that the set K(x, y) ≥ 0 of the (x, y) positive orthant denotes the
immune increasing region (see Subsection 5.1.1). Note that K(x(A), y(A)) = −b2 < 0.
By Theorem 5, if u(t) = 1 the state of model (6.1)-(6.5) converges to Point A.
Therefore, by continuity of K(x, y) with respect to x and y, there is a finite time T such
that K(x(T ), y(T )) < 0 and the state of the system is in a neighbourhood of Point A.
Consider an initial condition close to Point A and described by Xδ = (
λ
d
− δ1, δ2, δ3,
δ4, δ5). By the proof of Theorem 5, δ1, δ2, δ3, δ4, and δ5 are positive and sufficiently
small. Note, in addition, that
K˙ = c2y[ηβx(x− q − y) + λ− dx− (x− q)(a+ p1z1 + p2z2)]. (6.12)
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Then K˙(Xδ)
c2δ2
for u = 0 is given by
β
(
λ
d
− δ1
)(
λ
d
− δ1 − q − δ2
)
+ λ− d
(
λ
d
− δ1
)
−
(
λ
d
− δ1 − q
)
(a+ p1δ3 + p2δ5) >
β
(
λ
d
− δ1
)(
λ
d
− δ1 − q − δ2
)
−
(
λ
d
− δ1 − q
)
(a+ p1δ3 + p2δ5) >(
λ
d
− q − δ1
)(
β
λ
d
− a− βδ1 − p1δ3 − p2δ5
)
− βλ
d
δ2.
Since, by equations (6.6), (6.7), and (6.8),
(
λ
d
− q) and (β λ
d
− a) are positive then
K˙(Xδ) > 0 for u = 0 and δ1, δ2, δ3, δ4 and δ5 sufficiently small.
Using the above facts we provide some properties of model (6.1)-(6.5).
Figure 6.7: The curves K(x, y) = c2xy − c2qy − b2 = 0 (dotted), x˙ = λ− dx− βxy = 0
(dashed), and λ − dV = 0 (solid), where V = x+ y. The points (xi2, yi2) is defined as
the intersection of K = 0 and λ− dV = 0 in the (x, y) plane.
Proposition 1 Consider the model (6.1)-(6.5) and a state X(0) ∈ P which is suffi-
ciently close to Point A with x(0) + y(0) ≤ λ
d
. Suppose u(t) = 0 for t ≥ 0, and let X(t)
be the corresponding trajectory. Then there exists T > 0 such that X(T ) belongs to the
immune increasing region.
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Proof: As in the proof of Theorem 5, let V (t) = x(t) + y(t). Then V (t) ≤ λ/d for all
t ≥ 0 because we assume x(0) + y(0) ≤ λ/d (see the proof of Theorem 5). Consider now
the set α and the set β, as depicted in Figure 6.7. Note that the x component is not less
than x(E) and the y component is not greater than y(E) for any point in the set α ∪ β.
Moreover, by assumption, the point (x(0), y(0)) is located in the set α ∪ β, and z1(0),
w(0) and z2(0) are sufficiently small.
Since y(E) < y(C) = b1
c1
, z˙1 < 0 in the set α∪ β, which implies that z1(t) goes to zero
as long as the point (x, y) stays within the set α ∪ β. In addition z2(t) goes to zero as
long as the point (x, y) stays within the set α∪ β, since w˙ < 0 in the set α∪ β. Now, in
the set α ∪ β,
y˙ = y(βx− a− p1z1 − p2z2) ≥ δy,
for some positive δ, since x(t) > x(E) > q > a/β in the set α∪β by (6.7) (also see Figure
6.8).
For all (x, y) ∈ β, x˙ > 0 and y˙ ≥ δy. Hence for any (x(0), y(0)) ∈ β, (x(Tβ), y(Tβ))
enters the set α in a finite time Tβ > 0.
For all (x, y) ∈ α, x˙ < 0 and y˙ ≥ δy. Hence for any (x(0), y(0)) ∈ α, (x(Tα), y(Tα))
enters the immune increasing region (the upper region of the set K(x, y) = 0) in a finite
time Tα > 0. Note that the point (x, y) in the set α cannot enter the set β because
y˙ ≥ δy > 0 on the set x˙ = 0 which is the boundary between the set α and the set β
(part of the dashed line in Figure 6.7).
Hence the point (x, y) enters the immune increasing region in finite time. Moreover
the point penetrates into the immune increasing region passing through K(x, y) = 0,
x ∈ (x(E), xi2). 
Proposition 2 Consider the model (6.1)-(6.5) and a state X = (x, y, z1, w, z2). Assume
there exists u such that
x (x− q − y) ηβ + λ− dx ≥ (x− q) (a+ p1z1 + p2z2) . (6.13)
Then there is an input u which renders K˙(x, y) non-negative.
Proof: At the point (x, y), we have, by (6.12),
K˙(x, y) =c2y(ηβx(x− q − y) + λ− dx− (x− q)(a+ p1z1 + p2z2)).
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Note now that c2 and y are positive. Then, in order to render K˙(x, y) non-negative, we
need
ηβx(x− q − y) + λ− dx− (x− q)(a+ p1z1 + p2z2) ≥ 0.
Thus, if there is a value of u that renders inequality (6.13) true, then K˙(x, y) can be
rendered non-negative. 
The first term on the left-hand side of inequality (6.13) includes the input u via the
term η, which is multiplied by x (x− q − y)β. Therefore, to maximise the left-hand side,
u can be selected as
u =

 1, if y > x− q,0, if y < x− q. (6.14)
Note that by equation (6.14), u is chosen to render K˙ ≥ 0 whenever this is possible.
However (6.14) locally maximises w˙, as will be discussed in Subsection 6.2.5.
Proposition 2 is interpreted as follows. In the (x, y) plane, consider a state (x∗, y∗).
At this state, K = c2x
∗y∗ − c2qy∗ − b2 = K∗. The equation of the line K = K∗ in the
plane is
y =
K∗ + b2
c2
1
x− q .
Then the gradient of the line is
dy
dx
= −K
∗ + b2
c2
1
(x− q)2 .
The gradient of the line at the point (x∗, y∗) is
dy
dx
(x∗, y∗) = −(c2x
∗y∗ − c2qy∗ − b2) + b2
c2
1
(x∗ − q)2
= −y∗(x∗ − q) 1
(x∗ − q)2
= − y
∗
x∗ − q .
At the point (x∗, y∗), the time derivatives of the states x and y from (6.1) and (6.2) are
Vx :=
dx
dt
(x∗, y∗) = λ− dx∗ − ηβx∗y∗,
Vy :=
dy
dt
(x∗, y∗) = (ηβx∗ − a− p1z∗1 − p2z∗2) y∗.
The state can be driven into the area K ≥ K∗ if and only if
Vy ≥ − y
∗
x∗ − qVx
⇔x∗
(
1− y
∗
x∗ − q
)
ηβ +
λ− dx∗
x∗ − q − a ≥ p1z
∗
1 + p2z
∗
2 .
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Therefore, if there is a value of u that renders inequality (6.13) true with the selection
(6.14), then the state can be driven to the area K ≥ K∗ instantaneously.
6.2.3 The enhanced level of the immune system
Consider the set τ(yκ) defined in Subsection 6.1.1 by the inequalities y > 0, y < x− q,
x+ y < λ
d
+ ǫ, and y < yκ, where ǫ is any small positive number. Assume
6 yκ = y
(C) =
b1/c1 (Figure 6.8 depicts the set τ(yκ), with yκ = b1/c1).
Proposition 3 Consider the model (6.1)-(6.5) with the input u selected as in STEP 1
of the output feedback control. Then all trajectories of the model enter the set τ(yκ) in
finite time.
Proof: The state y is positive by Theorem 1. The state converges to Point A by
Theorem 5 and also x(t) + y(t) < λ
d
+ ǫ for all t ≥ tǫ for some tǫ > 0, from the proof of
Theorem 5, hence all trajectories of the model enter the set τ(yκ) in finite time. 
Proposition 4 Consider the model (6.1)-(6.5) with the input u selected as in STEP 2 of
the output feedback control. Then the set τ(yκ) is positively invariant, i.e., all trajectories
starting in τ(yκ) remain in τ(yκ) for all future time t.
Proof: The state y is positive by Theorem 1, and also x(t) + y(t) < λ
d
+ ǫ for all t ≥ tǫ
for some tǫ > 0 from the proof of Theorem 5. By condition (6.11), y˙ < 0 if u = 1 for
X ∈ P, from the proof of Theorem 5. To conclude the proof, x˙ must be greater than y˙
on the set
{
(x, y)| y = x− q, x ∈ [q, q + b1
c1
]
}
. Note that if λ− dx− ηβxy > y(ηβx− a)
with u = 1, then x˙ > y˙ on this set. The above condition rewrites as
λ− dx− (1− ǫ∗)βxy > (1− ǫ∗)βxy − ay
which is equivalent to
λ− aq > x[2(1 − ǫ∗)βx+ d− a− 2q(1− ǫ∗)β],
hence it is true because the left-hand term is positive by (6.8) and the right-hand term
is negative by condition (6.11). Hence all trajectories starting in τ(yκ) remain in τ(yκ)
for all future time t with the input u selected as in STEP 2. 
6A different selection for yκ will be discussed in Subsection 6.2.4.
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Note that Proposition 4 implies lim
t→∞
z1(t) = 0 by equation (6.3), and this property
will be useful in Chapter 7. Propositions 3 and 4 imply that the feedback control
guarantees that the state of the model (6.1)-(6.5), with the input as in STEPS 1 and 2,
does not converge to Point C (i.e. to the AIDS status). The set τ(yκ) contains points
Figure 6.8: The trapezoidal set τ(yκ) with yκ = y
(C) = b1
c1
and ǫ = 0. The dotted line
and the dashed line indicate the sets K(x, y) = 0 and y = yκ, respectively. The solid
line and the dash-dotted line represent the sets y + x = λ
d
and y = x− q, respectively.
in which K < 0 (see Figure 6.8). At STEP 1 in the feedback method the state enters
the set K < 0 in the set τ(yκ), and at STEP 2 the state enters the set K ≥ 0 in the
set τ(yκ). In the case of Figure 6.3 in Section 6.1, the states never returns to the set
K < 0 in the set τ(yκ). However, even if the state returns to the set τ(yκ) ∩(K < 0), the
feedback control method guarantees that the immune system (i.e., w and z2) is boosted
to a certain level, as discussed in the following statements.
Proposition 5 Consider the model (6.1)-(6.5) with the input u selected as in STEP 2 af-
ter the preliminary control action in STEP 1. Suppose that the states X = (x, y, z1, w, z2)
is on the line K(x, y) = 0 at t = T1 and T2 and that X(t) is in the set K(x, y) < 0,
for t ∈ [0, T1), and X(t) is in the set K(x, y) > 0 for t ∈ (T1, T2). Assume that K˙ is
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negative at t = T2. Then z2(T2) > z2m(x(T2)) and w(T2) > wm(x(T2)), where
z2m(x) =
1
p2
(
x
(
1− b2
c2(x− q)2
)
β +
λ− dx
x− q − a
)
, (6.15)
wm(x) =
hc1
c2qb1
z2m(x). (6.16)
Proof: Note that at t = 0, the state is sufficiently close to Point A by Theorem 5.
From Proposition 2, at t = T2,
x(T2)
(
1− y(T2)
x(T2)− q
)
ηβ +
λ− dx(T2)
x(T2)− q − a < p1z1(T2) + p2z2(T2).
Moreover, by Proposition 4, z1(T2) is negligible and u = 0 by the definition of the control
law. Hence
z2(T2) >
1
p2
(
x(T2)
(
1− y(T2)
x(T2)− q
)
β +
λ− dx(T2)
x(T2)− q − a
)
.
By Proposition 4, for 0 ≤ t ≤ T2,
z˙2 = c2qyw − hz2 < c2q b1
c1
w − hz2 ≤ c2q b1
c1
wM − hz2,
where wM is the maximum of w in the time interval 0 ≤ t ≤ T2. Then wM = w(T2)
because w(0) is sufficiently small and w monotonically increases to w(T2) in the interval
T1 ≤ t ≤ T27. By the comparison lemma (see [42, Lemma 3.4]), z2(T2) < c2qb1hc1 w(T2)
since z2(0) is sufficiently small. Hence z2(T2) > z2m(x(T2)) and w(T2) > wm(x(T2)). 
To show that the level of immune system in Proposition 5 is enough for the states
to be in the region of attraction of Point E for the model (6.1)-(6.5) with the given
system parameters, we use computer simulations. In these simulations it is assumed
that z1(0) = 0.0001, u = 0 (note that the input is constant), z2(0) = z2m(x(0)), and
w(0) = hc1
c2qb1
z2(0). We simulate with 50 pairs of initial points on the line K(x(0), y(0)) =
0 with x(0) regularly spaced between xi3 and xi2 (see Figure 6.9)
8.
The bottom graph of Figure 6.9 shows a zoomed-in version of the top graph. All
considered initial states yield trajectories which converge to the LTNP state (πE mark).
The trajectory with x(0) = xi3 is displayed with a dashed line in the top graph. This
7By the assumptions of Proposition 5, wM is w(0) or w(T2). If wM = w(0), then z2(T2) goes to zero
by (6.5). Hence wM = w(T2) by contradiction.
8The point (xi3, yi3) is defined as the intersection of y = x− q and λ−dx−βxy = 0. Note that x˙ > 0
regardless of u (either u = 0 or u = 1) in the region λ − dx − βxy > 0 in the set τ (yκ). Therefore the
state cannot reach K(x, y) = 0 for x ∈ [xi1, xi3] in the set τ (yκ).
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Figure 6.9: Simulations for 500 days with 50 initial points on the line K(x, y) = 0,
(x ∈ [xi3, xi2]), the levels of w(T2) and z2(T2) in Proposition 5, and the condition u = 0.
(xi3, yi3) is the intersection of y − (x − q) = 0 and λ − dx − βxy = 0. The “·”and the
“+”marks denote the projections on the (x, y) plane of the initial points and of the final
points, respectively. The dashed line represents the (x, y) trajectory with the initial
condition x(0) = xi3 on the line K(x, y) = 0.
trajectory goes outside the set τ because we use a constant u = 0 instead of the output
feedback controller in the simulation of Figure 6.9.
We now study if the (x, y) trajectory stays within the set τ(yκ) ∩(K < 0) for a long
time. To this end we provide a general property of the HIV dynamic model, by which
we conclude that if the (x, y) state enters the set τ(yκ) ∩(K < 0) during the output
feedback control, then the state cannot remain there but has to return to the set τ(yκ)
∩(K > 0).
Proposition 6 Consider the model (6.1)-(6.5) and assume X(t) ∈ τ(yκ)∩(K < 0) with
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u(t) = 0 for t ∈ (−T3, 0] where T3 is sufficiently large and positive9. Let X(t) be the
corresponding trajectory with u(t) = 0 for t ≥ 0. Then there exists T4 ≥ 0 such that
X(T4) belongs to the immune increasing region.
Figure 6.10: The lines K(x, y) = 0 (solid), V = λ/a (dashed), and V = λ/d+ ǫ (dotted)
where V = x + y and ǫ = 0. The point (xi4, yi4) is the intersection of K = 0 and
λ− aV = 0, while (xi2, yi2) is the intersection of K = 0 and λ− dV = 0.
Proof: Consider the set γ defined by the inequalities K < 0, y > 0, V > λ/a, and
V < λ/d + ǫ where ǫ is any small positive number, as depicted in Figure 6.10. The
points (xi1, yi1) and (xi2, yi2) are defined in Figure 6.8. As in the proof of Theorem 5,
let V (t) = x(t) + y(t). Then V (t) < λ
d
+ ǫ for all t ≥ tǫ for some tǫ > 0 (see the proof of
Theorem 5). In addition x˙ = λ− dx− βxy > λ− (d+βyi1)x in the set τ(yκ) ∩ (K < 0)
with u = 0. Note that d+ βyi1 < a by (6.10), hence x(0) >
λ
a
by assumption. Thus the
point (x(0), y(0)) is located in the set γ.
9This assumption is established as the worst condition for enhancing w and z2. However this assump-
tion implies that the uninfected CD4 T-cells (x) and the infected CD4 T-cells (y) stay in the vicinity of
the curve λ− dx− βxy = 0 in the set τ (yκ) ∩ (K < 0), which is ironically a good clinical condition for
a HIV patient (see Figure 6.10). Note that the immune response for HIV does not need to be boosted
if this clinical condition is maintained.
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Figure 6.11: The grey region indicates the set τ(yκ) where yκ =
1
75y
(C). The dash-dotted
line, the dotted line, and the solid line describe the sets λ− dx− βxy = 0, K(x, y) = 0,
and the (x, y) trajectory, respectively (top graph). From yκ, we obtain the corresponding
xκ from the top graph and z2m of (6.15) from the bottom graph.
By assumption, z1(0) and z2(0) are sufficiently small. Note that z1(t) goes to zero
(z˙1 < 0 by y < yi4 < y
(C))10, and that z2(t) goes to zero by w˙ < 0 in the set γ. Then the
states does not cross the line λ − aV = 0 because V˙ (t) > λ − aV (t) − p1z1y − p2z2y >
λ− aV (t)− p1z1(0)yi4 − p2z2(0)yi4. In addition
y˙ = y(βx− a− p1z1 − p2z2) ≥ δy,
for some positive δ because xi4 > q >
a
β
by (6.7) and x(t) > xi4 in the set γ. Hence the
state enters the immune increasing region through K(x, y) = 0, x ∈ (xi4, xi2). 
6.2.4 The enhanced level of the immune system with a smaller yκ
From Figure 6.9 we infer that the guaranteed levels of the immune system can be changed
using a different value of yκ. To this end we consider the set τ(yκ) where yκ =
1
75y
(C),
10K = 0 and λ+ aV = 0 have two intersections in the positive orthant if and only if b2
c2
< 1
4
 
λ
a
− q
2
.
In addition, if b1
c1
> 1
2
 
λ
a
− q

, the smaller real part of the y components of the intersections becomes
less than b1
c1
. Therefore yi4 < y(C) by (6.9) and (6.10).
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Figure 6.12: Results of the application of the output feedback control scheme to model
(6.1)-(6.5) with the set τ(yκ) where yκ =
1
75y
(C). The unit of x and y is (100copies/µl).
as depicted in the top graph of Figure 6.11. Note that Propositions 3 and 4 still hold for
this set τ(yκ), and the inequalities y
(E) < yκ ≤ y(C) still hold in Figure 6.11. If we assign
a smaller yκ, a larger xκ and a larger z2m in (6.15) are obtained from the top graph and
the bottom graph in Figure 6.11, respectively. The point (xκ, yκ) is the intersection of
the boundary of the set τ(yκ) and λ− dx− βxy = 0. Note that xκ = λd+βyκ in this case,
because the intersection is on the line y = yκ.
We perform a simulation of the control procedure of Section 6.1 with the set τ( 175y
(C))
and the same initial conditions used in Section 6.1. Figure 6.12 shows the results.
Compared with the case of the set τ(y(C)) in Section 6.1, the case of the set τ( 175y
(C))
requires longer control efforts (over 750 days) and shows slower enhancement of the
immune system (compare Figure 6.2 and Figure 6.12), while it theoretically guarantees
greater boosted level of the immune system from (6.15).
6.2.5 Interpretation of the condition L2(x, y) = 0
In this subsection we discuss how to select u(t) to locally (in time) maximise w(t). This
is realised by a numerical method. Consider model (6.1)-(6.5), i.e., X˙(t) = f(X(t), u(t))
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Figure 6.13: Results of the application of the on-line selection of u to maximise the
increase of w, for model (6.1)-(6.5). The unit of x and y is (100copies/µl).
with X = [x, y, z1, w, z2]
T . With a sufficiently small δT and the current state value
X(t), we obtain an approximation of X(t+ δT ) by the classical 4th order Runge-Kutta
method [45], namely,
X(t+ δT ) = X(t) +
1
6
(k1 + 2k2 + 2k3 + k4), (6.17)
where
k1 = δTf(X(t)),
k2 = δTf(X(t) + 0.5k1),
k3 = δTf(X(t) + 0.5k2),
k4 = δTf(X(t) + k3).
As a result, an approximation of w(t + δT ), calculated by (6.17), is a function of u(t)
and we can select u(t) to locally maximise w(t + δT ). To implement this strategy, we
find u(t) satisfying
max
u(t) ∈ UE
w(t+ δT ),
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Figure 6.14: The (x, y) trajectory resulting from the on-line strategy. The dotted line
and the solid line indicate the set K(x, y) = 0 and the (x, y) trajectory, respectively. The
dashed line and the dash-dotted line represent the sets L1(x, y) = 0 and L2(x, y) = 0,
respectively.
where, for example, UE = {0.01, 0.02, · · · , 1} and δT = 0.00001.
Figure 6.13 shows the results of the application of this method. The system para-
meters are as in the previous simulations, while the initial condition is X(0) = (0.2913,
3.3333, 0.0913, 0.0001, 0.0001), sufficiently close to Point C. The resulting (x, y) trajec-
tory is displayed in Figure 6.14, which shows that the (x, y) trajectory moves along the
sets L2(x, y) = 0 in the middle of the treatment.
Therefore the condition L2(x, y) = 0 of the output feedback scheme in Section 6.1
implies local maximal growth of w.
6.3 Conclusion
We have provided an output feedback control method for HIV drug therapy. The immune
boosting mechanism yielded by the control law has been discussed and supported by
formal statements. We have also shown that the proposed idea guarantees a minimal
activation of the immune system. The applicability of the method is demonstrated by
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means of computer simulations. The works in this chapter are included in [23] and [18].
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Chapter 7
Approximate estimation of
immune states in HIV dynamics
Control methods based on the understanding of the boosting mechanism of the immune
response have been proposed in Chapter 5 and Chapter 6. The purpose of this chapter is
to provide approximate estimation methods for the states of the immune system of the
HIV patient on the basis of available measurements. We show the applicability of these
state inference ideas by means of numerical simulations. The results in this chapter are
presented in the work of [20].
The methods in this chapter rely on approximations hence we use the terminology
state inference rather than state observer. Note that the inference of the immune states
is not used in feedback control loop in this chapter (see Figure 7.1). The purpose of this
chapter is just to monitor the CTL response in HIV dynamics (2.1)-(2.5).
To begin with we recall model (2.1)-(2.5) of Section 2.1.1, namely
x˙ = λ− dx− ηβxy, (7.1)
y˙ = ηβxy − ay − p1z1y − p2z2y, (7.2)
z˙1 = c1z1y − b1z1, (7.3)
w˙ = c2xyw − c2qyw − b2w, (7.4)
z˙2 = c2qyw − hz2. (7.5)
The model (7.1)-(7.5) with u = 0 has five equilibrium points, three of which are recalled
from Table 3.1, for convenience, as given in what follows.
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Figure 7.1: Diagram describing the connections of the HIV model, the controller, and the
state estimator. The block inside the dotted-line indicates the HIV dynamics (7.1)-(7.5),
which consist of two subsystems, the infection dynamics and the immune system.
Point A:
x(A) =
λ
d
, y(A) = 0, z1
(A) = 0, w(A) = 0, z2
(A) = 0;
Point C:
x(C) =
λc1
dc1 + b1ηβ
, y(C) =
b1
c1
, z1
(C) =
ηβx(C) − a
p1
, w(C) = 0, z2
(C) = 0;
Point E:
y(E) =
c2(λ− dq)− b2ηβ −
√
[c2(λ− dq)− b2ηβ]2 − 4ηβc2qdb2
2ηβc2q
, x(E) =
λ
d+ ηβy(E)
,
z1
(E) = 0, w(E) =
hz2
(E)
c2qy(E)
, z2
(E) =
y(E)(c2ηβq − c2a) + b2ηβ
c2p2y(E)
.
In Chapter 6 we have shown that an output feedback can be designed to boost the
immune response of the human body to steer the system to Point E, i.e. the LTNP
status.
In this chapter we suggest state estimation methods for the state of the immune
system of model (7.1)-(7.5). The methods are aimed to be used during the STEP 2,
defined in Section 6.1. Note that we do not need any state estimation during STEP 1,
defined in Section 6.1, because the state converges to Point A by Theorem 5. Also z1
does not need to be estimated in STEP 2 because it converges towards 0, as shown in
Proposition 4.
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7.1 State inference of immune system via continuous out-
put measurement
For model (7.1)-(7.5), assume the following.
1. z1(t) is zero.
2. x and y are the system outputs and are twice differentiable1.
Consider now the functions
γz2(x, x˙, y, y˙) =
λ− dx− ay − x˙− y˙
p2y
, (7.6)
and
γw(x, x˙, x¨, y, y˙, y¨) =
1
c2qp2y2
[(
h− y˙
y
)
(λ− dx− ay − x˙− y˙)− (dx˙+ ay˙ + x¨+ y¨)
]
.
(7.7)
By (7.1), (7.2), and the assumption on z1(t), γz2(x, x˙, y, y˙) = z2. Then, by (7.5), the
function γw(x, x˙, x¨, y, y˙, y¨) is such that
1
c2qp2y
[
h
y
(λ− dx− ay − x˙− y˙)−
(
y˙
y2
(λ− dx− ay − x˙− y˙) + 1
y
(dx˙+ ay˙ + x¨+ y¨)
)]
=
1
c2qp2y
[
h
1
y
(λ− dx− ay − x˙− y˙) + d
dt
(
1
y
(λ− dx− ay − x˙− y˙)
)]
=
1
c2qy
(hz2 + z˙2) = w.
Note that the assumption on z1(t) is acceptable during STEP 2 since z1(t) decreases
exponentially by Proposition 5 and Proposition 4 during the drug treatment (see Section
6.1). Consequently, z1(t) becomes sufficiently small for all t in STEP 2 and negligible
as time goes by. Also note that we obtain an approximation of a differentiator from the
assumption on the continuous measurability of the state x and y. See Figure 7.2 for the
implementation of an approximate differentiator with a transport delay.
As a result of the above discussion, approximations of w and z2 are given by
z2 ∼= γz2(x,D(x, δT ), y,D(y, δT )) (= zˆ2),
w ∼= γw(x,D(x, δT ),D(D(x, δT ), δT ), y,D(y, δT ),D(D(y, δT ), δT )) (= wˆ),
1This implies that x and y are continuously measurable.
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Figure 7.2: Diagram describing an implementation of approximate differentiator in
Simulink using transport delay.
where D(x, δT ) = (x(t)− x(t− δT ))/δT (see Figure 7.2).
This state approximation idea is denoted as state inference via continuous output
measurement (SIC). Two simulations of SIC have been carried out for the examples from
Subsection 6.1.1. The time ranges of the graphs are selected to show the performance
of SIC and we consider the errors
ew = w − wˆ,
ez2 = z2 − zˆ2.
Figure 7.3 shows the result of SIC in the interval [50, 100] for the case in Figure 6.4.
The variables w(t) and z2(t) of model (7.1)-(7.5) are depicted with dotted lines in the
first and third graph, respectively. For wˆ(t) and zˆ2(t), the parameter δT is 0.05.
From the assumption on double differentiability of the state x and y, SIC cannot
guarantee good performance in the interval [20, 50], because this interval includes too
many switches between 0 and 1 of the input function u(t). The switchings render x˙ and
y˙ discontinuous, by equations (7.1) and (7.2), which implies that x¨ and y¨ are not defined
for all t.
However we can apply SIC in the time interval [20, 200] for the case in Figure 6.5,
because this case has only a few input switching instants and we can use SIC piece by
piece2 for each period in which the input is constant. Note that a constant u(t) implies
twice differentiable system outputs, x(t) and y(t), by (7.1) and (7.2).
Figure 7.4 shows wˆ and ew, particularly in the interval [26, 38]. Note that the time
range of the bottom graph is [20, 200] although the time ranges of the top and middle
graphs are [26, 38]. w(t) and wˆ(t) are depicted with the dotted line and the solid line,
2This implies that the inferences of z2 and w do not exist for the first δT and 2δT periods after each
input switching, respectively (see the definition of D(·, δT ) and Figure 7.2). Note that wˆ and ew in
Figure 7.4 are discontinuous at each input switching instant.
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Figure 7.3: State histories of state inference via continuous output measurement for the
example in Figure 6.4 for the time interval [50, 100].
respectively, in the top graph. ew is displayed with the solid line in the middle and
bottom graphs. A rescaled u(t) is plotted with dashed line as a square wave function in
the middle graph. The third graph in the figure confirms the performance of SIC in the
whole time period [20, 200]. zˆ2 and ez2 are not shown in the figure, and the parameter
δT is selected equal to 0.01.
7.2 State inference of immune system via discrete output
measurement
Although SIC is a good state approximation for the immune system, we consider an
alternative state approximation method because the continuous output injection in SIC
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Figure 7.4: State histories of state inference via continuous output measurement and of
the errors for the example in Figure 6.5. Note that wˆ and ew are discontinuous at each
input switching instant.
is hardly implementable in practice. In fact the levels of x and y are measured at
discrete time instants from patient’s blood samples (see Section 2.2 for a discussion
on HIV measurements). This implies that currently we cannot use SIC which requires
continuous measurement of x and y. We denote the state approximation idea in this
section as state inference via discrete output measurement (SID).
Firstly we infer z2(t) for the example in Figure 6.5, where x and y are measured every
0.25 day. The approximation idea stems from [57, Section III.A]. We can approximately
calculate x˙ and y˙ from two samples of x and y, respectively. Also approximations of x¨
and y¨ can be obtained from three samples of x and y, respectively.
We assume that z1 is sufficiently small because y(t) is such that y(t) <
b1
c1
. Then, by
(7.1) and (7.2),
z2 =
λ− dx− ay − x˙− y˙
p2y
,
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Figure 7.5: State inference via discrete output measurement of z2 for the example in
Figure 6.5 with 1 sample each 0.25 (day). In the top graph, z˜2 is the state approximation
of z2 by state inference via discrete output measurement. z˜2 is given by points each 0.25
(day), while z2 is shown with the solid line.
and the SID of z2, denoted by z˜2, is plotted in Figure 7.5. In the first graph the solid
line corresponds to z2(t) from the model (7.1)-(7.5) and the points indicate z˜2, every
0.25 (day) in the time interval [26, 38]. The second graph shows the error between z2
and z˜2 from the first graph. The last graph presents the overall performance of the SID
of z2 in the time interval [20, 200]. We see that discrete-time measurements of x and y
can be used to estimate the level of z2.
The variable w is inferred using the same method. By equation (7.5)
w =
1
c2q
(
z˙2 + hz2
y
)
,
and an approximation of z˙2 is obtained from z˜2. However z˜2 is oscillating in the interval
[26, 36], which makes the SID of w unreliable in this interval. This oscillation is caused
by the switching of the input u between 0 and 1. If the input u is changed from 1 to 0
(or vice-versa) at a certain instant, then z˜2 is not reliable by (7.1) and (7.2) because x˙
and y˙ are not continuous.
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Figure 7.6: State inference via discrete output measurement of w for the example in
Figure 6.5 with 4 samples each 0.25 (day). In the top graph w˜ is the state approximation
of w by state inference via discrete output measurement. w˜ is given by points at each
0.25 (day), while w is shown with the solid line.
To overcome this problem in z˜2, we apply the method used in the previous section. By
multiple measurements in each period, where the input u is guaranteed to be constant,
we reliably obtain not only z˜2 but also w˜, the SID of w as shown in Figure 7.6. From
the ideas in [57], three measurements of x and y are needed to approximate x¨ and y¨,
respectively, although we use four measurements3 to infer w in Figure 7.6.
7.3 Conclusion
We have presented two state approximation methods to monitor the immune status in
a HIV dynamic model. In the first method we suggest an approximate estimation (i.e.,
3Suppose that the four measurements are carried at T , T + δ, T + 2δ, and T + 3δ. For example, we
infer z2(T + δ) based on the measurements at T and T + 2δ. Similarly we infer z2(T + 2δ) based on the
measurements at T + δ and T +3δ. By these infered z2(T + δ) and z2(T +2δ) we approximately obtain
z˙2 and also the inference of w.
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SIC) which requires continuous output injection from the HIV dynamic system. The
second method (i.e., SID) allows to infer the states of the immune system using only
three (or four) measures of x and y if the system parameters are known. The works in
this chapter are included in [20]. We complete this chapter with some remarks.
1. The function γw in Section 7.1 does not depend on the w dynamics (7.4) except for
c2 and q which are scaling factors. Thus we do not need any information on (7.4)
in order to see the trend of w. This implies that we can use extremum seeking
methods for the boosting of the immune term w regardless of (7.4). This will be
the subject of future research.
2. While state inference methods show promising performance, measurement noise
and model uncertainty problems should be researched in detail.
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Chapter 8
Conclusion
The primary goal of this thesis is to steer the state of the system describing a HIV
infected patient to the LTNP status. This is achieved by means of new methods of
treatment.
The first method, described in Chapter 3, is based on an approximation of higher
order dynamics by a reduced order model. For the approximation we divide the HIV
infection model into two subsystems and modify one of the subsystems to emulate the
whole system. With the modification we relieve the difficulties associated with the high
order model, such as state observation and parameter estimation.
The second control method, discussed in Chapter 4, is known as gradual reduction
of drug dose. By this scheme it is possible to steer the state of any patient to the LTNP
status if the model parameters belong to certain parameter intervals. In order to justify
the claim, we first analyze the stability and the bifurcation properties of a HIV model
and show that there exists an equilibria curve towards the LTNP, which is locally stable
for almost every fixed constant input.
The third control method, studied in Chapter 5, is derived from a new control phi-
losophy which aims at boosting the response of the immune system by means of drug
scheduling. The control strategy is implemented by controlled drug scheduling based
on the understanding of the immune boosting mechanism. The feasibility of the control
methodology is illustrated via simulations on a general disease model and on three HIV
dynamic models, one of which is a tristable HIV dynamic model.
This control perspective yields an output feedback method to control the immune
response in Chapter 6. The suggested output feedback control idea guarantees that
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the immune state is enhanced to a certain level, which is enough for a typical patient
to be driven into the long-term nonprogressor. To justify the control methodology the
resulting controlled HIV dynamic model is studied analytically.
Finally, in Chapter 7, we investigate methods to approximate the state of the immune
system on the basis of available outputs of the HIV model. To this end we suggest two
state estimation methods, denoted as state inferences.
8.1 Main contribution
The main part of this research relies on a property of the immune system in a HIV model.
The property is that excitement of a key component in the immune system depends on
the infection dynamic states, which correspond to HIV infected cells and uninfected cells.
Interestingly these two states can be measured by clinical methods and moreover they
are directly affected by antiretroviral drugs, which are used in HIV antiviral-drug ther-
apy. Therefore we propose control methods of drug scheduling to enhance the response
of the immune system. The methods are based on the comprehension of the immune
boosting mechanism, and also can be applied to various biological systems, which de-
scribe infection dynamics with drug input. Consequently this thesis provides guidelines
for drug scheduling to strengthen the immune system of an infected patient.
8.2 Future work
1. In this work we assume the immune system is clearly modeled by differential equa-
tions but the human immune system is too complicated to be modeled with a
few differential equations, thus unmodeled parts of the immune system must be
considered. To overcome such a modeling-limitation problem, we can exploit adap-
tive control methods, such as extremum seeking and the method used in Section
3.4. Extremum seeking methods might be suitable to maximize the immune sys-
tem without precise immune system modeling, and the method of Section 3.4 is
available for partly modeled problem by means of parameter adaptation.
2. The input term used in this thesis is the idealized therapy effect to the human
body. Although the input function obtained from the control procedure can drive
the patient state into the region of attraction of the LTNP, the realization of the
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function in the human body could be difficult, because the function is a square
wave. Therefore further consideration for the drug delivering mechanisms must be
researched. For example a modeling method to describe biobarriers between drugs
and their target is used for cancer chemotherapy [63,81].
3. The proposed control methods are simple and powerful to boost the immune sys-
tem, as seen in the simulations. However alternative control laws can be investi-
gated because the methods in this thesis do not consider the cost of drugs, side
effects of HAART, the duration of the anti-HIV therapy, and noise in the HIV
measurements. Finally constraints on the levels of HIV and CD4 T-cells must be
considered during the medication.
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